Cell therapy
By genetically enhancing PHGDH expression in cells, particularly CAR T cells, the issue of cell persistence and survival is addressed, resulting in improved therapeutic outcomes for cancer and infections.
Patent Information
- Application Number
- CN202380029264.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-22
- Filing Date
- 2023-03-22
- Publication Date
- 2024-12-06
AI Technical Summary
Existing cell therapies, particularly CAR T cell therapies, face challenges with insufficient cell persistence and survival, leading to relapse in patients with cancer and infections, despite their initial effectiveness.
Genetically engineering cells to enhance expression of phosphoglycerate dehydrogenase (PHGDH), which functions as an RNA binding protein to regulate cell differentiation and survival, thereby improving cell persistence and reducing apoptosis.
Enhanced PHGDH expression in cells, such as CAR T cells, leads to improved persistence and survival in vivo, addressing the limitations of current cell therapies by ensuring effective treatment duration and efficacy.
Smart Images

Figure BDA0005052851050000101 
Figure BDA0005052851050000102 
Figure BDA0005052851050000111
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of regenerative medicine, in particular cell therapy, and provides compositions and methods for treating cancer and / or infection in patients. The present invention provides cells, preferably immune cells, genetically engineered to enhance PHGDH expression, as well as expression constructs, vectors, and methods for preparing and using the same.
[0002] Sequence Listing
[0003] The sequence listing associated with the present application (HORN_002_001WO_SeqList_ST26.xml; size: 14,059 bytes; and creation date: March 17, 2023) is provided in electronic form in lieu of a paper copy and is hereby incorporated by reference in its entirety. Background Art
[0004] Cell therapy is the transfer of whole living cells into a patient to treat a disease or condition. Cells may originate from the patient (autologous cells) or from a donor (allogeneic cells), and recent developments have enabled the use of cells from a different organism (xenogeneic).
[0005] Adoptive cell therapy (also called cellular immunotherapy) is a form of cell therapy that uses cells of our immune system to treat a disease or condition.
[0006] Our immune system is able to recognize and eliminate cells that have become infected or damaged, as well as those that have become cancerous. In the case of cancer, cells called cytotoxic T cells (CTLs or CD8 + Immune cells called T cells are particularly powerful due to their ability to bind to appropriate cell surface molecules on cancer cells, called antigens.
[0007] CD8 + T cells are critically involved in protecting the host from viruses, intracellular bacteria, and malignant cells. During acute infection, naive CD8 + T(T NV ) cells are initiated in the lymph nodes, clonally expand, and differentiate into primary effector cells. The effector cells then leave the lymph nodes, enter the bloodstream and migrate to the site of inflammation, where they secrete cytokines and kill infected cells. Once the pathogen is cleared, most effector cells undergo apoptosis during the contraction phase, while a small fraction of antigen-specific CD8 +T cells differentiate to form a memory pool. A defining characteristic of memory T cells is their ability to re-expand and acquire effector functions more rapidly than their naive counterparts when encountering the same antigen (secondary effector cells), thereby achieving improved efficacy in containing reinfection. Reflecting the tissue of the recall response, there are various memory T cell subsets that differ in migration patterns and tissue distribution, phenotype, and functional properties. Human central memory (T CM ) and effect memory (T EM )CD8 + T cells are readily available in the peripheral blood. The former recirculate between the bloodstream and lymph nodes, and the latter return from the blood circulation to different peripheral tissue sites.
[0008] CD4 + T cells display a diverse repertoire of effector functions and exhibit considerable phenotypic plasticity and heterogeneity depending on the local context and microenvironment. + The key role of T cells is to modulate the state and function of other immune cells. + T cells are crucial for optimal antitumor responses, including cancer immunotherapy, due to their inherent ability to coordinate diverse immune responses and their flexible differentiation into different effector lineages. + T cells promote antitumor responses through different major strategies, such as direct antitumor activity through the production of IFN-γ and TNF-α. + T cells secrete IL-2, which drives CD8 + Effector function, differentiation and proliferation of CTLs and direct activation of CD8 + CTL.CD4 + T cells by supporting and maintaining proinflammatory cross-presenting dendritic cells (DCs), which in turn activate CD8 + T cells) and CD8 + T cells provide indirect help. CD4 + T cells are also indispensable for inducing humoral responses against tumor antigens by coordinating antibody production.
[0009] Cancer patients may have endogenous T cells that are able to target their cancer cells. + T cells in particular are able to recognize and destroy cancer cells with great precision. However, the presence of these cells does not necessarily mean that they are sufficient to eliminate the tumor. The cells must also be able to remain active in sufficient numbers for a long enough time to maintain an effective anti-tumor response.
[0010] Some adoptive cell therapy approaches involve directly isolating our own immune cells and expanding the number of said immune cells (e.g., TILs) prior to reinfusion, while other approaches involve genetically engineering immune cells to enhance the effector function of said immune cells (e.g., CAR T cells). In particular, the chimeric antigen receptor (CAR) T cell approach is emerging as a strategy with the highest potential for treating disease, particularly cancer (e.g., various malignancies).
[0011] CAR T cell therapy relies on redirecting T cells to appropriate cell surface molecules on cancer cells and has shown promising results in harnessing the power of the immune system to treat malignancies and other cancers. Gamma-retroviral and lentiviral transduction methods are most commonly used in genetically engineered CAR T cells due to their high transduction efficiency. Most currently available CAR-T therapies are manufactured using lentiviruses. Therapies using CAR T cells have shown very promising results in a variety of tumor types, particularly in the treatment of hematological malignancies. In 2017, the first two CAR T cell therapies, Kymriah (tisagenlecleucel, Novartis) and Yescarta (axicabtagene ciloleucel, Gilead), received FDA approval. Both therapies are approved for patients with specific hematological cancers that are refractory to standard therapies or for relapsed disease. Such patients were previously considered incurable and had few treatment options.
[0012] Natural killer (NK) cell therapy is another form of adoptive cell therapy. These NK cells can also be equipped with cancer-targeting CARs.
[0013] Tumor infiltrating lymphocyte (TIL) therapy is an adoptive cell therapy approach that utilizes naturally occurring T cells that have infiltrated a patient's tumor. The cells are activated and expanded ex vivo and then infused back into the patient.
[0014] Engineered T cell receptor (TCR) therapy is another adoptive cell therapy approach that involves taking T cells from a patient and equipping them with new T cell receptors that target specific cancer antigens, allowing physicians to choose the best target for each patient's tumor and the different types of T cells to engineer.
[0015] Cell therapy has also been studied for the treatment of infectious diseases, particularly viral diseases, such as chronic hepatitis B, CMV infection, EBV and HIV or opportunistic fungal infections. Studies have shown that viral infections or relapses developed in immunosuppressed patients (e.g., patients with human cytomegalovirus or EBV reactivation after hematopoietic stem cell or organ transplantation) respond to adoptive immunotherapy using autologous in vitro amplified virus-specific T cells derived from memory or naive T cell populations (Houghtelin A. et al., 2017, Front. Immunol. 8: 1272. doi: 10.3389 / fimmu.2017.01272).
[0016] Although CAR T cells have achieved great success in treating certain hematological malignancies, not all patients respond to adoptive cell therapy. A significant portion of patients treated with CAR T cells experience relapse, and CAR T cell-based solid cancer treatment remains a significant obstacle. In addition to the ability of CAR to genetically modify T cells to recognize and destroy target cells, successful therapeutic T cell therapy also requires the ability to proliferate and persist over time and further monitor tumor cell escape. Therefore, engineering CAR T cells to improve their survival and, therefore, persistence represents a logical therapeutic approach to enhance the therapeutic potential of the CAR T cells.
[0017] There is still a need in the art for improved cell therapies, particularly improved adoptive cell therapies, such as CAR T cell therapies with improved survival and / or persistence. These cell therapies will provide more effective treatments for diseases such as cancer and infection. Summary of the invention
[0018] In a first aspect, the present invention provides a cell genetically engineered to enhance expression of phosphoglycerate dehydrogenase (PHGDH).
[0019] In a second aspect, the present invention provides an expression cassette comprising a polynucleotide sequence encoding phosphoglycerate dehydrogenase (PHGDH).
[0020] In a third aspect, the present invention provides a vector comprising a polynucleotide sequence encoding phosphoglycerate dehydrogenase (PHGDH), optionally wherein the polynucleotide sequence comprises SEQ ID NO:4 or a sequence with 95% identity to SEQ ID NO:4, and wherein the sequence encodes a polypeptide having RNA binding activity, or a variant or functional fragment thereof.
[0021] In a fourth aspect, the present invention provides a cell comprising an expression cassette as described herein or a vector as described herein.
[0022] In a fifth aspect, the present invention provides a composition comprising a cell as described herein, an expression cassette as described herein or a vector as described herein.
[0023] In a sixth aspect, the present invention provides a method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a cell as described herein, an expression cassette as described herein, a vector as described herein, or a composition as described herein.
[0024] In a seventh aspect, the present invention provides a cell as described herein, an expression cassette as described herein, a vector as described herein or a composition as described herein for use in a method of treating a disease or disorder in a subject.
[0025] In an eighth aspect, the present invention provides a method for producing cells genetically engineered to enhance expression of phosphoglycerate dehydrogenase (PHGDH), the method comprising contacting one or more cells with a vector as described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1A Schematic diagram showing the T cell isolation and sorting strategy.
[0027] Figure 1B Shown are RNAseq (upper panel) and proteomics data (lower panel) in freshly sorted human T NV and T EM Biological processes that are overrepresented in the transcripts / proteins that are differentially expressed between cells. NV Compared with T cells EM GO term enrichment analysis was performed for transcripts / proteins with reduced abundance in cells. The 20 biological processes with the lowest p-values in each analysis are shown in rank order. According to MetaCore (Clarivate Analytics).
[0028] Figure 1C Comparison of T from healthy human donors (n=4) is shown. NV and T EM Volcano plot of RNAseq- (left panel) and proteomic (right panel) analysis of cells. Detected transcripts / proteins related to serine metabolism are shown in red. adj Hits < 0.05 are marked in dark blue if log2FC > 0.5, or in cyan if log2FC < 0.5.
[0029] Figure 1DShown is the analysis of freshly sorted T NV 、T EM and T CM Western blot of SSP enzyme expression in cells. Data are representative of two independent experiments.
[0030] Figure 1E Schematic representation of the SSP enzyme (green), the serine-permeable amino acid transporter (yellow), and enzymes representing linkage to one-carbon metabolism (blue).
[0031] Figure 1F Is the analysis of T NV 、T EM and T CM Representative Western blots of the expression of proteins involved in serine metabolism in T cells. T cells remained unstimulated (-) or activated for 24 h using beads coated with anti-CD3 / CD28 mAb (+) (left panel). PHGDH protein abundance was quantified by densitometry, normalized for actin, and compared with the activated T cells of each corresponding donor. EM The abundance of PHGDH in cells is shown (3 independent experiments, right panel).
[0032] Figure 1G Proliferation assessed by CFSE dye dilution 5 days after activation is shown. The bar graph summarizes the percentage of cells that have diluted the dye for at least one cell division (n=3, left panel). T cells from one human donor NV 、T CM and T EM Representative histograms of CFSE dilutions of cells (right panels). Data are presented as mean ± SD (F, G). P values were determined using paired two-tailed Student's t-test. *P < 0.05, **P < 0.01; ns, not significant.
[0033] Figure 2AComparison of putative RNA binding sites in GAPDH (left) and PHGDH (right) is shown. Structural features of GAPDH involved in RNA binding are highlighted (reference 5) and compared to PHGDH. The Rossman fold domains of each two interacting subunits are shown in green (α-helix) and blue (β-sheet), while R163 is marked in red (top panel). Electrostatic potential of surface residues. The yellow line highlights regions with high positive potentials that may be involved in electrostatic interactions with negatively charged RNA (middle panel). Dimer interface. For GAPDH, the two five-stranded β-sheet groups are shown in black and orange, one color per subunit—the rest of the protein is shown in light gray ribbons. In the interface shown, one subunit has been removed for clarity—except for the residues at the interface. For PHGDH, the dimer interface is shown in black and orange, one color per subunit—the rest of the protein is shown in light gray ribbons, with R163 marked in red (bottom panel).
[0034] Figure 2B Shown in PHGDH WT (WT) and PHGDH KO The specificity of the PHGDH-antibody (#66350, D8F30, Cell Signaling) used in the RIPseq experiment was tested on (KO) Jurkat T cell lysates and total protein staining (left panel). PHGDH and isotype control antibodies were used to stain sorted T cells 36 h after activation. NV IPs for RIPseq experiments were performed and validated by Western blotting (n=3, right panels). RNA was isolated from each IP sample and sequenced in parallel with the input sample.
[0035] Figure 2C is a volcano plot of transcript abundance in PHGDH-IP versus input (left panel) and isoform-IP versus input (right panel). Red (upper) dots indicate p adj <0.05 significantly differentially expressed transcripts, while blue (lower) dots indicate transcripts that were not significantly enriched after IP. Of the 927 transcripts enriched in the isoform IP, 637 were also enriched in the PHGDH-IP.
[0036] Figure 2D is a scatter plot of RIPseq data showing the enrichment of each transcript relative to the input using PHGDH-IP (x-axis) versus isoform IP (y-axis). Pull-down was defined as specific when the RNA species (i) was enriched >2-fold in PHGDH-IP compared to the input, and (ii) was enriched more than 2-fold in PHGDH-IP compared to the isoform IP.
[0037] Figure 2E Shown are the relative abundance of pro-survival genes in PHGDH (left bars) and isoform (right bars) IP samples detected in the RIPseq experiment.
[0038] Figure 2F Schematic diagram of RNAseq experiment after CRISPR-Cas9-induced PHGDH gene editing (n=5).
[0039] Figure 2G Volcano plot of differentially expressed transcripts (RNAseq after gene editing) in primary effector T cells expressing PHGDH vs. depleted PHGDH 72 h after activation.
[0040] Figure 2H is a Venn diagram of hits detected by RNAseq- and RIPseq experiments. Overlaps represent transcripts defined as PHGDH targets by RIPseq that are also functionally responsive upon PHGDH depletion (RNAseq). Transcripts associated with regulation of gene expression, development, and survival are highlighted in boxes.
[0041] Figure 3A PHGDH mRNA expression in spleen (Sp) murine T cell subsets according to the ImmGen database is shown. Naive (T.8.Nve.Sp), LCMV-specific central memory (T8.Tcm.LCMV.d180.Sp) and effector memory CD8 + Normalized expression values for T cells (T8.Tem.LCMV.d180.Sp). Annotations are copied from ImmGen.
[0042] Figure 3B The expression of CD62L and CD44 for murine CD8 + T NV and T EM Sorting strategy for cells (left panel). Bar graph depicts PHGDH levels quantified by intracellular flow cytometry in spleen TNV and TEM cells (n=5 mice, middle panel). NV and T EM Western blot of SSP enzymes in cells (pooled cells from 5 mice, right panel).
[0043] Figure 3C OVA-specific OT-IT cells (Thy1.1 + ) is a schematic diagram of the adoptive transfer experiment.
[0044] Figure 3D Shown is a Western blot analyzing PHGDH expression in OT-I T cells transduced with EV or OE-PHGDH prior to adoptive transfer.
[0045] Figure 3E Figure 3 shows the expression of Thy1.1 transduced with EV or OE-PHGDH during LmOva infection. + GFP + The frequency of T cells (n=8-9, left panel). The bar graph shows the frequency of Thy1.1 at 7dpi and 14dpi. + GFP + Frequency of T cells (middle and right panels).
[0046] Figure 3F Figure 2 shows the expression of Thy1.1 transduced with EV (lower line), wild-type PHGDH (OE-WT) (middle line), or catalytically dead PHGDH (OE-CD) (upper line) during LmOVA infection (n=5). + GFP + The frequency of T cells.
[0047] Figure 3G Figure 2 shows Thy1.1 transduced with EV or OE-CD during infection at 35 dpi following LmOVA infection. + GFP + Frequency of T cells (n=5). Data are presented as mean±SD (B) or ±SEM. P values were determined using an unpaired two-tailed Student's t-test.
[0048] Figure 4A T cells were electroporated with negative gRNA (sg-Cont) (right peak) or PHGDH-gRNA (sg-PHGDH) (left peak) and then activated with anti-CD3 / CD28 mAb for 96 hours. NV Representative histograms of PHGDH expression in .
[0049] Figure 4B Figure 2 depicts the T used for electroporation with sg-Cont or sg-PHGDH 96 h after activation. NV Figure 2. Dot plots of the gating strategy for distinguishing viable, late, and early apoptotic cells in T cells electroporated with sg-Cont (left bar) or sg-PHGDH (right bar) 96 h after activation. NV The frequencies of viable, late, and early apoptotic cells in the 400 cells / well were analyzed (n=3, right panel).
[0050] Figure 4CIs a dot plot depicting the gating strategy for sorting CD19 CAR T cells (CAR only) and CD19 CAR_PHGDH(CD) T cells (CAR_PHGDH(CD)) according to GFP and mCherry expression (left panel). Relative cell numbers of CD19 CAR T cells and CD19 CAR_PHGDH(CD) T cells normalized to the number of CD19 CAR T cells at 2-4 days (n=3-4, right panel).
[0051] Figure 4D Western blot analysis of PHGDH expression in CD19 CAR T cells and CD19 CAR_PHGDH T cells is shown (n=2).
[0052] Figure 4E Schematic diagram of the experimental design (left panel). + CD45 + Frequency of T cells (n=4-8, right panel). Data are presented as mean±SEM. P values were determined using unpaired two-tailed Student's t-test. *P<0.05, **P<0.01.
[0053] Figure 5A is a schematic diagram of the experimental design.
[0054] Figure 5B CD3 + CD45 + Splenic CD3 T cells + CD45 + Frequencies of T cells, CD8+ T cells, and CD4+ T cells (n=9).
[0055] Data are presented as mean ± SEM. P values were determined using unpaired two-tailed Student's t-test. *P < 0.05, **P < 0.01.
[0056] Fig. 6A The results show that after CRISPR-Cas9-induced knockout of PHGDH, T NV PHGDH and IRF1 transcript levels in WT mice (n=5). Data are presented as mean ± SEM. P values were determined using an unpaired two-tailed Student's t-test. *P<0.05, ****P<0.0001.
[0057] Figure 6B PHGDH and IRF1 protein levels after CRISPR-Cas9-induced knockout of PHGDH are shown (n=4). Data are expressed as mean ± SEM. P values were determined using an unpaired two-tailed Student's t-test. *P<0.05, ****P<0.0001.
[0058] Figure 6C is a schematic diagram of the experimental design of the actinomycin D chase experiment.
[0059] Fig.6D Figure 2 shows the analysis of WT (negative gRNA) or PHGDH knockout (PHGDHgRNA) CD8+ T cells before actinomycin D chase experiment. NV Western blotting of PHGDH and IRF1 expression in cells.
[0060] Fig. 6E Figure 3 shows WT (negative gRNA; bottom line) or PHGDH knockout (PHGDH gRNA; top line) CD8+ T cells after 0, 1, 2, and 3 hours of actinomycin D treatment. NV IRF1 mRNA levels in cells (n=3).
[0061] Fig. 7A Schematic diagram of the IRF1-3'UTR fragment used for microscale thermophoresis experiments.
[0062] Figure 7B Shown are normalized binding curves of fragment 3 (Fg3, green; lower line) and fragment 4 (Fg4, red; upper line) at concentrations ranging from 850 nM to 13 nM in the presence of 50 nM recombinant PHGDH protein.
[0063] Figure 7C Normalized binding curves of Fg3 (green; lower line) and mutant fragment 3 (muFg3, red; upper line) at concentrations ranging from 850 nM to 13 nM in the presence of 50 nM recombinant PHGDH protein are shown. Data Fit K d Model. DETAILED DESCRIPTION
[0064] The present invention is based in part on the discovery that T cells (T EM ) compared with phosphoglycerate dehydrogenase (PHGDH) in naive T cells (T NV Surprisingly, PHGDH was identified in T NV cells, but not in T EM More specifically, the inventors have demonstrated that in CD8 +During the transition of T cells from effector cells to memory cells, PHGDH expression is downregulated. The inventors have identified PHGDH as a non-metabolic effect of RNA binding protein (RBP) showing RNA binding activity, and the RNA binding activity is related to the regulation of cell differentiation and survival. The inventors have demonstrated that by strengthening PHGDH expression in cells to be transplanted (such as immune cells to be transplanted as part of adoptive immune cell therapy, particularly T cells, preferably CAR T cells), the enhanced persistence of cell therapy can be achieved in vitro and in vivo.
[0065] Therefore, the present invention solves the above-mentioned needs in the art. For example, the present invention meets the needs in the field of cell therapy by providing improved cell therapy, expression constructs, vectors and methods for preparing and using the same. Specifically, the present invention solves the problem of insufficient cell persistence in the field of regenerative medicine, especially cell therapy, preferably adoptive cell therapy, preferably CAR T cell therapy. The present disclosure provides a cell therapy that improves the persistence of cells to be transplanted. The present disclosure provides an improved cell therapy in applications where it is important to increase the persistence of transplanted cells. In a preferred aspect, the present disclosure provides an improved adoptive immune cell therapy, wherein the immune cells are preferably lymphocytes, preferably T cells, preferably CAR T cells. Therefore, the present disclosure provides an improved cancer therapy or an improved infection treatment.
[0066] Phosphoglycerate dehydrogenase (PHGDH) is an enzyme that catalyzes the first and rate-limiting step of the L-serine biosynthetic pathway (SSP) in animal cells (also referred to herein as L-serine biosynthetic pathway catalytic enzyme activity or PHGDH catalytic activity). In humans, PHGDH may comprise or consist of the following amino acid sequence:
[0067] Human WT PHGDH (SEQ ID NO: 1)
[0068] sp|O43175|SERA_HUMAN D-3-phosphoglycerate dehydrogenase OS=Homo sapiens OX=9606GN=PHGDH PE=1SV=4
[0069]
[0070] Human WT PHGDH may be encoded by the following PHGDH gene in humans:
[0071] Human PHGDH (WT) - NCBI reference sequence: NM_006623.4 (SEQ ID NO: 2)
[0072]
[0073]
[0074] PHGDH can include one or more mutations that reduce the activity of the L-serine biosynthetic pathway catalytic enzyme or completely knock out this activity (so-called "catalytically inactive" variant of PHGDH - "PHGDH (CD)"). PHGDH catalytic activity can be measured using techniques known in the art, such as using a commercial PHGDH catalytic activity kit (Abcam, ab273328) to measure, or as described herein. PHGDH can include one or more mutations in the catalytic domain of PHGDH to reduce or knock out PHGDH catalytic activity. For example, PHGDH can be a PHGDH (CD) comprising an R236E mutation (as described in Mattani et al. Cancer & Metabolism (2015) 3:5; DOI: 10.1186 / s40170-015-0131-7). In humans, PHGDH (CD) may include or consist of the following amino acid sequence:
[0075] PHGDH(CD)R236Eaa sequence (SEQ ID NO:3), R236 mutation is highlighted
[0076]
[0077] PHGDH(CD)R236E may be encoded by the following sequence:
[0078] Human PHGDH (CD) (SEQ ID NO: 4)
[0079]
[0080]
[0081] Metabolic enzymes can also participate in non-metabolic or "moontime" effects, which leads to the possibility of functional incompatibility at the cellular level. The inventors have confirmed the non-metabolic or moontime effects of PHGDH. Specifically, the inventors have demonstrated that PHGDH is silent during the contraction of effector T cells. The inventors have demonstrated that PHGDH has a moontime role as an RNA binding protein, exhibits RNA binding activity, and this property helps to regulate the persistence of T cells. The inventors have demonstrated how the catalytically inactive variants of PHGDH (e.g., PHGDH (CD) R236E) can retain RNA binding activity. Research on such variants helps to clarify the non-metabolic RNA binding effect of PHGDH.
[0082] In one aspect, the invention provides a cell genetically engineered to enhance expression of PHGDH.
[0083] The term "enhanced expression" and similar terms refer to the transcription of a gene or transgene into messenger RNA (mRNA) by a cell and the translation of the mRNA into a polypeptide (i.e., a gene or transgene product). The expression of a gene or transgene can be measured at the mRNA level (e.g., by sequence-specific quantification of mRNA levels in a cell) or at the polypeptide level (e.g., by measuring the level of a polypeptide gene product using Western blotting, densitometry, enzyme-linked immunosorbent assay (ELISA), immunofluorescence microscopy, or other means of quantifying a specific polypeptide) by techniques known in the art. "Enhanced expression" means the expression of a gene, transgene, or polypeptide that is not expressed under normal conditions, or the expression of a gene or polypeptide is greater than the expression of a given cell (e.g., any of the cells described herein) under normal conditions. The enhanced expression can be measured by comparing a test cell (e.g., a genetically engineered cell as described herein) with a reference or control cell (e.g., a cell that has not been genetically engineered as described herein or a cell that has been genetically engineered but contains an empty vector or otherwise does not contain a transgenic cell as described herein) under the same or similar conditions. Suitably, the control cells are derived from the same cell population as the test cells, wherein the cell population is used in a cell therapy, wherein the test cells are genetically engineered as described herein. The enhanced expression of PHGDH may be in one or more cells that do not express PHGDH (e.g., T cells described herein). EM ) is greater than 0. Enhanced expression of PHGDH can be a measure of increased expression of PHGDH mRNA and / or polypeptide in one or more test cells compared to one or more control cells, suitably, the expression of PHGDH mRNA and / or polypeptide in the one or more test cells is increased by more than 1 fold, such as at least 1.1 fold or more, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 1.6 fold, 1.7 fold, 1.8 fold, 1.9 fold, 2 fold, 3 fold, 4 fold, 5 fold, or at least 10 fold.
[0084] As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
[0085] The expression of PHGDH can be enhanced by genetically engineering the cell to incorporate an exogenous polynucleotide sequence encoding PHGDH (e.g., using a vector comprising an exogenous polynucleotide sequence encoding PHGDH) or by altering the endogenous expression of PHGDH (e.g., by preventing or reducing silencing of PHGDH expression, or by increasing the expression of endogenous PHGDH, such as by increasing the activity of one or more endogenous promoter and / or enhancer regions associated with the PHGDH gene).
[0086] The data provided herein show that PHGDH can show a part-time role as an RNA binding protein (RBP) with RNA binding activity. Studies have shown that PHGDH shows RNA binding activity in T cells, and the activity is related to the regulation of cell differentiation and survival. Therefore, PHGDH expression can promote the persistence of cells and / or prevent cell death, such as reducing the apoptosis of effector T cells during the contraction phase.
[0087] RNA binding activity can be determined by methods known in the art and as disclosed herein, for example, using one or more RNA electrophoretic mobility shift assays (EMSA), RNA pull-down assays including RNA immunoprecipitation sequencing (RIPseq) and RNA sequencing (RNAseq), RNA enzyme H protection assays for targeted oligonucleotides, fluorescent in situ hybridization co-localization assays, and microscale thermophoresis (MST). In preferred aspects, the PHGDH as described herein has RNA binding activity, preferably wherein the PHGDH binds to one or more mRNAs encoding transcripts regulating pro-apoptotic and / or pro-survival processes within a cell, preferably a cell as described herein, preferably a T cell, and / or one or more mRNAs encoding epigenetic modifiers and / or WNT signaling components. In a preferred aspect, PHGDH binds to one or more mRNAs encoding transcripts selected from BBC3, MCL1, TP53BP2, NFKBIA, IRF1, BCL2, KDM3A, DOT1L, KAT2A, KDM6B, DVL1 and Jun; preferably one or more mRNAs encoding transcripts regulating pro-apoptotic and / or pro-survival processes, the transcripts preferably being selected from BBC3, MCL1, TP53BP2, NFKBIA, IRF1 and BCL2. In a preferred aspect, PHGDH binds to one or more mRNAs encoding transcripts regulating pro-apoptotic processes (preferably IRF1), preferably wherein PHGDH reduces the stability of mRNAs encoding transcripts regulating pro-apoptotic processes (preferably IRF1) and / or shortens their mRNA half-life. In one aspect, PHGDH shortens the half-life of mRNAs as described herein (preferably IRF1) to 90%, 80%, 70%, 60%, 50% or less. In one aspect, PHGDH shortens the half-life of an mRNA as described herein (preferably IRF1) from 150 minutes to about 75 minutes. In another aspect, PHGDH binds to one or more mRNAs containing AU-rich elements (AREs) (preferably multiple AREs in the 3'UTR). In one aspect, PHGDH is an ARE binding protein (ARE-BP). mRNA can be detected by methods known in the art and as described herein, preferably by RIPseq and / or RNAseq; the binding of PHGDH to mRNA can be detected by methods known in the art and as described herein, preferably by actinomycin D tracking experiments and / or microscale thermophoresis.
[0088] In one aspect, the PHGDH as described herein has RNA binding activity, wherein the PHGDH binds to RNAs that are: (i) >2-fold enriched in the PHGDH-IP compared to the input (total cell lysate), and (ii) more than 2-fold enriched in the PHGDH-IP when compared to the control (isoform-IP) in the RIPseq assay described herein. Suitably, in the RIPseq assay described herein, preferably in T cells, the PHGDH binds to about 200 or more, such as about 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or about 2000 or more RNAs, preferably to about 1500 or more protein-coding RNAs.
[0089] In one aspect, PHGDH may have RNA binding activity, but without or with reduced PHGDH catalytic activity. In a preferred aspect, PHGDH may be included in one or more mutations in the PHGDH catalytic domain to reduce or knock out PHGDH catalytic activity, but retain RNA binding activity, as described herein. PHGDH catalytic activity can be measured by techniques known in the art and as described herein, such as by using a bioreader (excited at 360nm and emitted at 460nm; including PSAT1 and its substrate glutamate to prevent product inhibition of PHGDH) monitoring NADH fluorescence over time, such as Xu H. et al., 2021, J.Biol.Chem.296: 100572, the document is hereby incorporated by reference in its entirety. In one aspect, the PHGDH may comprise a mutation at one or more positions selected from 108, 119, 121, 133, 135, 140, 163, 236, 279 and 283 of SEQ ID NO: 1; preferably selected from 108, 121, 236 and 283; preferably selected from 236 and 283; preferably 236. In one aspect, the PHGDH may comprise one or more mutations selected from E108A, R119A, I121A, W133A, R135A, R135W, G140R, R163Q, R236E, I279A, H283A; preferably selected from E108A, I121A, R236E and H283A; preferably selected from R236E and H283A; preferably R236E. In a preferred aspect, a PHGDH comprising one or more mutations as described herein results in a PHGDH having a catalytic activity lower than that of PHGDH WT, such as about 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1% or less catalytic activity compared to PHGDH WT (SEQ ID NO: 1). In a preferred aspect, PHGDH may comprise one or more mutations that render PHGDH catalytically inactive but retain RNA binding activity, preferably PHGDH (CD) comprises the amino acid sequence of SEQ ID NO: 3, wherein PHGDH has RNA binding activity as described herein.
[0090] The PHGDH as described herein may comprise or consist of the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 3 or a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 1 or SEQ ID NO: 3, wherein the polypeptide has RNA binding activity as described herein, or a functional fragment or variant thereof. Preferably, the PHGDH as described herein comprises or consists of SEQ ID NO: 3 or a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 3, wherein the polypeptide has RNA binding activity, or a functional fragment or variant thereof.
[0091] In one aspect, the disclosure provides a cell genetically engineered to enhance PHGDH expression, wherein the cell is used in a cell therapy as described herein. The disclosure provides a cell genetically engineered to enhance PHGDH expression, wherein the cell is useful or can be used in a cell therapy or method as described herein.
[0092] Cell therapy is a therapy that provides or administers living cells to a subject. Cells can be transplanted (e.g., injected, transplanted, or infused) into a subject to treat a condition or disease. It is desirable to enhance the persistence of cells to be transplanted into a subject as part of a cell therapy to treat a condition or disease, particularly in adoptive cell therapy (e.g., CAR T cell therapy).
[0093] Cells as described herein can be any cells that can be used for regenerative medicine, such as cells for cell therapy as described herein. In preferred aspects, cells as described herein can be any regenerative medicine that can be used to benefit from increased cell persistence, preferably cell therapy, preferably cells for adoptive cell therapy that will benefit from increased persistence of transplanted cells. In one aspect, the cell can be any regenerative medicine, preferably cell therapy, preferably cells for adoptive cell therapy in which PHGDH expression is downregulated or silenced along with differentiation. Downregulation or silencing of PHGDH expression along with differentiation can be determined by methods known in the art and as described herein, such as Western blotting, real-time reverse transcription PCR, epigenetic analysis. In preferred aspects, the cell can be an immune cell, a neuron, or a mammary epithelial cell, a prostate epithelial cell, or a colon epithelial cell. In one aspect, the cell can be any regenerative medicine, preferably cell therapy, preferably cells for adoptive cell therapy that will benefit from the regulation of apoptosis and / or pro-survival processes.
[0094] Adoptive cell therapy, also known as cellular immunotherapy, is a form of cell therapy that uses cells of the mammalian immune system, preferably the human immune system, to treat a condition or disease, particularly cancer. In a preferred aspect, any of the cells described herein, particularly cells genetically engineered to enhance PHGDH expression as described herein, can be adoptive cell therapy, including tumor infiltrating lymphocytes (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, or natural killer (NK) cell therapy, preferably any cell used in CAR T cell therapy.
[0095] The cells of the immune system can be classified as lymphocytes (including T cells, B cells and NK cells), neutrophils and monocytes / macrophages. Cells as described herein can be any immune cell, preferably lymphocytes. The term "lymphocyte" as used herein refers to any mononuclear non-phagocytic leukocyte derived from lymphoid stem cells found in blood, lymph and lymphoid tissues. Lymphocytes include T cells, natural killer (NK) cells and B cells, CIK (cytokine-induced killing) cells and combinations thereof.
[0096] T cells are a type of lymphocyte (T lymphocyte) that develops in the thymus and plays a central role in immune responses. T cells can be distinguished from other lymphocytes by the presence of T cell receptors on the cell surface. These immune cells originate from precursor cells derived from the bone marrow and develop into several different types of T cells once they have migrated to the thymus. T cells continue to differentiate after leaving the thymus. The cells described herein can be any T cell, such as CD3 + cells, helper CD4 + T cells, cytotoxic CD8 + T cells, memory T cells, regulatory CD4 + T cells, natural killer T cells or γδ T cells or a combination thereof, preferably cytotoxic CD8 + T cells.
[0097] Natural Killer cells or NK cells are a type of cytotoxic lymphocyte that is critical to the innate immune system. NK cells play a role similar to that of cytotoxic T cells in the adaptive immune response of vertebrates. NK cells provide a rapid response to virus-infected cells and respond to tumor formation.
[0098] Tumor infiltrating lymphocytes (TIL) are white blood cells that have left the bloodstream and migrated toward a tumor. They include T cells and B cells, and are a component of a larger category of 'tumor infiltrating immune cells', which is composed of mononuclear immune cells and polymorphonuclear immune cells (e.g., T cells, B cells, natural killer cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, basophils, etc.) in different proportions. Their abundance varies with tumor type and stage, and is related to disease prognosis in some cases. TIL can be used in cell therapy, wherein TIL is separated from the patient's tumor and amplified in vitro. Amplified TIL can then be subjected to specific tumor recognition assays, and then tumor-specific TIL is reinfused into the patient, optionally after an additional amplification step, tumor-specific TIL is reinfused into the patient.
[0099] In a preferred aspect, the cell as described herein, in particular the cell genetically engineered to enhance PHGDH expression as described herein, is a T cell, a NK cell, a B cell or a combination thereof; preferably a T cell or a NK cell, preferably a T cell, preferably a CD3 + cells, preferably CD8 + T cells and / or CD4 + T cells. In various aspects, the cell may comprise a CAR or a modified TCR. In various aspects, the cell may be an antigen-specific cell, preferably a tumor antigen or a viral antigen-specific cell, preferably an antigen-specific T cell.
[0100] In one aspect, the present disclosure relates in part to a plurality of cells as described herein, in particular a plurality of cells genetically engineered to enhance PHGDH expression as described herein. In a preferred aspect, the plurality of cells may include a plurality of T cells, NK cells, B cells, or a combination thereof; preferably T cells, NK cells, or a combination thereof; preferably a plurality of T cells, preferably CD3 + cells, preferably CD8 + T cells and / or CD4 + T cell, which optionally comprises a CAR.
[0101] As described herein, one or more cells can be allogeneic (where the cells are derived from a subject different from the subject receiving the transplanted cells), autologous (where the cells are derived from the subject's own tissue), or xenogeneic (where the cells are derived from another species). In a preferred aspect, the cells are autologous.
[0102] In one aspect, one or more cells as described herein can be genetically engineered to strengthen the expression of PHGDH by incorporating an exogenous polynucleotide encoding PHGDH ("PHGDH transgene") into the cell. In another aspect, the cell as described herein can be genetically engineered to strengthen the expression of PHGDH by enhancing the endogenous expression of PHGDH. For example, the expression of endogenous PHGDH can be increased by changing the activity of one or more regulatory elements, such as increasing the activity of one or more endogenous promoters and / or enhancers or inhibiting the inhibitory region associated with the PHGDH gene by methods known in the art. For example, the promoter of the endogenous gene encoding PHGDH can be modified so that the gene encoding PHGDH is constitutively expressed in the cell. Similarly, the silencing of endogenous PHGDH expression can be prevented or reduced by inhibiting the epigenetic silencing of PHGDH. Methods for genetic engineering are well known in the art and include CRISPR / Cas9, or use engineered nucleases, such as meganucleases, zinc finger nucleases or TALENs.
[0103] Exogenous polynucleotides, such as polynucleotide sequences encoding PHGDH as described herein, can be incorporated into one or more cells, such as one or more cells as described herein, and expressed in the cells by techniques known in the art and as disclosed herein. Methods for incorporating polynucleotides (such as genes and transgenics) into cells and expressing the genes and transgenics are known in the art and include physical, chemical and biological methods. Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipid transfection, particle bombardment, microinjection, electroporation. Chemical methods for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles and liposomes. Biological methods for introducing polynucleotides of interest into host cells include the use of viral vectors.
[0104] The practice of the present invention employs, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the knowledge of those skilled in the art. Such techniques are fully explained in the literature, such as "Molecular Cloning: A Laboratory Manual", Second Edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (MJ Gait, ed., 1984); "Animal Cell Culture" (RI Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (DM Weir & C.C. Blackwell, ed.); "Gene Transfer Vectors for Mammalian Cells" (JM Miller and MP Calos, ed., 1987); "Current Protocols in Molecular Biology" (FM Ausubel et al., ed., 1987); "PCR: The Polymerase Chain Reaction" (Mullis et al., ed., 1994); and "Current Protocols in Immunology" (JE Coligan et al., ed., 1991), each of which is expressly incorporated herein by reference.
[0105] As used herein, the term "transgene" refers to a polynucleotide sequence to be inserted into a cell, which encodes a polypeptide or a portion of a polypeptide to be expressed in the cell. The PHGDH transgene may include a nucleic acid sequence that is not naturally present in the cell (i.e., a heterologous nucleic acid sequence encoding PHGDH); a nucleic acid sequence that is a variant or mutant form of a nucleic acid sequence that is naturally present in the cell; or a nucleic acid sequence that is naturally present in the cell.
[0106] The term "encoding" refers to the inherent property of a specific nucleotide sequence in a polynucleotide (e.g., a coding sequence, gene, cDNA, or RNA) to be used as a template for the synthesis of other polymers and macromolecules having a defined nucleotide sequence (e.g., rRNA, tRNA, and mRNA) or a defined amino acid sequence and the resulting biological properties in a biological process. Thus, if a coding sequence or gene is transcribed into mRNA and translation of the mRNA corresponding to the coding sequence or gene produces a protein in a cell or other biological system, then the coding sequence or gene encodes the protein.
[0107] As used herein, "vector" refers to a macromolecule or macromolecular association that contains or associates with a polynucleotide and can mediate the delivery of the polynucleotide to a cell. Illustrative vectors include, for example, plasmids, viral vectors, liposomes, and other gene delivery vehicles. For example, viral vector methods (e.g., retroviral and lentiviral (LV) vectors) utilize a variety of vectors and have been well characterized in the art. One or more plasmid vectors can be used to transfect cells, preferably in vitro (e.g., in HEK-293 cells) to generate viral particles (viral vectors), such as viral vectors (expression vectors) containing expression cassettes as described herein.
[0108] A vector comprising a polynucleotide encoding a gene product of interest and implementing the expression of the gene product in the intended target cell may be referred to as an "expression vector". An expression vector may comprise a control element (e.g., a promoter, an enhancer, a UTR, a miRNA targeting sequence, a joint, a tag, etc.) that is operably connected to a polynucleotide or region encoding a gene product of interest to promote the expression of the gene product in the target cell. The combination of a control element and a polynucleotide or region encoding a gene product of interest to which the control element is operably connected for expression is referred to herein as an "expression cassette". Many such control elements are known and available in the art, or may be easily constructed from components available in the art.
[0109] Any of the cells, expression cassettes and vectors as described herein may comprise a polynucleotide sequence encoding PHGDH as described herein. Suitably, PHGDH is PHGDH WT, PHGDH with reduced catalytic activity as described herein, or PHGDH (CD) with RNA binding activity, preferably PHGDH is PHGDH with reduced catalytic activity as described herein, or PHGDH (CD) wherein PHGDH has RNA binding activity as described herein. In various aspects, the polynucleotide sequence includes SEQ ID NO: 2 or SEQ ID NO: 4 or a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with SEQ ID NO: 2 or SEQ ID NO: 4, wherein the sequence encodes a polypeptide having RNA binding activity, or a functional fragment or variant thereof. In a preferred aspect, the polynucleotide sequence encoding PHGDH comprises SEQ ID NO:4, or a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:4, wherein the sequence encodes a polypeptide having RNA binding activity, or a functional fragment or variant thereof.
[0110] As used herein, "variant" or "mutant" means a polynucleotide or polypeptide having less than 100% sequence identity with a reference polynucleotide or polypeptide, such as a "wild-type" polynucleotide or polypeptide or a polynucleotide or polypeptide naturally present in a cell. Relative to a reference polynucleotide sequence, a variant or mutant polynucleotide may comprise at least one nucleotide difference (e.g., a nucleotide substitution, a nucleotide insertion, or a nucleotide deletion); relative to a reference polypeptide sequence, a variant or mutant polypeptide may comprise at least one amino acid difference (e.g., an amino acid substitution, an amino acid insertion, or an amino acid deletion). In some aspects, a variant or mutant polynucleotide or variant or mutant PHGDH polypeptide encoding PHGDH retains the biological activity of a wild-type PHGDH, including L-serine biosynthetic pathway catalytic enzyme activity as described herein and / or RNA binding activity as described herein; preferably RNA binding activity.
[0111] In some aspects, the disclosure provides an expression cassette comprising a polynucleotide sequence encoding a phosphoglycerate dehydrogenase PHGDH as described herein. The expression cassette can be adapted to be used for genetic modification of cells, such as any cell as described herein that can be used for cell therapy, preferably immune cells, preferably T cells. The expression cassette can be adapted to be used to enhance PHGDH expression in cells, such as any cell, preferably immune cells, preferably T cells that can be used in cell therapy as described herein. The expression cassette can be adapted to be used for genetic modification of cell therapy as described herein, preferably adoptive cell therapy, preferably T cell therapy.
[0112] The expression cassette of the present disclosure may include a polynucleotide sequence encoding PHGDH as described herein; and a control element that controls the expression of PHGDH in a cell, such as any cell as described herein, preferably a cell that can be used in cell therapy as described herein, preferably an immune cell, preferably a T cell. The control element may be selected from one or more of a promoter, an enhancer, a miRNA targeting sequence, a linker, and a tag, preferably wherein the control element is operably linked to a polynucleotide or region encoding a gene product of interest.
[0113] The expression cassette of the present disclosure can increase the expression of PHGDH in the cells of the present disclosure, preferably by expressing the PHGDH transgene in the cells. As used herein, "expression of a transgene" or "expressing a transgene" refers to transgene transcription into messenger RNA (mRNA) by a host cell and translation of the mRNA into a polypeptide (i.e., a transgenic product). Therefore, the expression of PHGDH can be measured at the mRNA level (i.e., by sequence-specific quantification of the mRNA levels in the cell) or at the polypeptide level (i.e., by measuring the level of the polypeptide gene product using Western blotting, enzyme-linked immunosorbent assay (ELISA), immunofluorescence microscopy, or other means of quantifying a specific polypeptide).
[0114] PHGDH transgenes can be modified or "codon optimized" to enhance expression by replacing infrequently expressed codons with more frequently expressed codons. The coding sequence is the portion of the mRNA sequence that encodes the amino acid for translation. During translation, each of the 61 trinucleotide codons is translated into one of the 20 amino acids, resulting in degeneracy or redundancy in the genetic code. However, different cell types and different animal species utilize tRNAs (each carrying an anticodon) encoding the same amino acid at different frequencies. When a gene sequence contains codons that are infrequently expressed by the corresponding tRNA, the ribosomal translation mechanism may be slow, thereby hindering effective translation. Expression can be improved via "codon optimization" for a specific species, in which the coding sequence is changed to encode the same protein sequence, but using highly expressed codons, and / or codons used by highly expressed human proteins (Cid-Arregui et al., 2003; J. Virol. 77: 4928).
[0115] As used herein, "promoter" encompasses nucleotide sequences that direct the binding of RNA polymerase and thereby promote RNA synthesis (i.e., initiate transcription). Promoters and corresponding protein or polypeptide expression may be ubiquitous (meaning strongly active in a wide range of cells, tissues, and species) or cell type-specific, tissue-specific, or species-specific. Promoters may be "constitutive," meaning continuously active, or "inducible," meaning that the promoter can be activated or inactivated by the presence or absence of biotic or abiotic factors.
[0116] As used herein, "enhancer" encompasses cis-acting elements that stimulate or inhibit transcription of adjacent genes. Enhancers that inhibit transcription are also referred to as "silencers". Enhancers are nucleic acid elements known in the art that enhance transcription and can be located at any position (e.g., upstream, downstream, introns) associated with the gene it regulates. Enhancers can play a role in any orientation at a distance of up to several thousand base pairs (kb) from the coding sequence and from a position downstream of the transcription region. Enhancer sequences affect promoter-dependent gene expression.
[0117] Promoter and enhancer elements can be tissue-specific or stage-specific. For example, a tissue-specific promoter or enhancer preferentially drives expression (or higher levels of expression) in one or more specific cell types. A stage-specific promoter or enhancer preferentially drives expression (or higher levels of expression) during one or more specific stages of the cell cycle or development.
[0118] Any suitable promoter, such as a promoter region or a promoter sequence in the promoter, can be used in the subject expression cassette, as long as the promoter promotes the expression of PHGDH in the cells described herein, preferably eukaryotic cells, preferably mammalian cells, preferably human cells, preferably immune cells, preferably T cells. The promoter can be a constitutive promoter or an inducible promoter, preferably an inducible promoter. In a preferred aspect, the promoter can be selected from CMV, EF1A, EFS, CAG, CBh, SFFV, MSCV, SV40, mPGK, hPGK, UBC or TRE promoter.
[0119] Any suitable enhancer can be used in the subject expression cassettes, so long as the enhancer enhances PHGDH expression in the cells described herein, particularly when used in combination with any promoter described herein.
[0120] The polynucleotide sequence encoding PHGDH can be heterologous to the promoter sequence to which the polynucleotide sequence is operably linked (i.e., not naturally operably associated with the promoter sequence) or endogenous to the promoter sequence to which the polynucleotide sequence is operably linked (i.e., naturally operably associated with the promoter).
[0121] In a preferred aspect, the expression cassette as described herein may include a sequence encoding a chimeric antigen receptor (CAR). The present disclosure provides an expression cassette, the expression cassette comprising a polynucleotide sequence encoding phosphoglycerate dehydrogenase (PHGDH) and a polynucleotide sequence encoding CAR, as described herein. The expression cassette is suitably a polycistronic expression cassette for expressing multiple proteins in a single vector. The polynucleotide sequence encoding PHGDH and the polynucleotide sequence encoding CAR can be separated or flanked by one or more joints using techniques known in the art, and the joint is preferably selected from one or more internal ribosome entry sites (IRES) or one or more polynucleotides encoding "self-cleavage" peptides, and the "self-cleavage" peptides are, for example, selected from P2A, T2A, E2A and F2A or a combination thereof Self-cleavage 2A peptides. The coding sequences separated by IRES sequences are each independently translated. 2A peptides are 18-22 amino acid long viral oligopeptides that mediate "cleavage" of polypeptides during translation in eukaryotic cells.
[0122] The expression cassette of the present disclosure may include the following general structure: 5'-promoter-CAR-linker-PHGDH-3'; 5'-promoter-PHGDH-linker-CAR-3'; wherein the promoter may be a sequence encoding any promoter in the promoter described herein, CAR may be a sequence encoding any CAR in the CAR described herein, PHGDH may be any polynucleotide sequence in the polynucleotide sequence encoding PHGDH as described herein, and the linker may be any one of the linker sequences as described herein or the polynucleotides encoding the linker sequences. The expression cassette may further include a polynucleotide sequence in the region between one or more of the promoter, PHGDH, linker and CAR sequences at the 5' end, the 3' end, and the CAR sequence. For example, the expression cassette as described herein may include one or more tags, preferably at the 3' end, preferably selected from mCherry, GFP, any fluorescent tag, CD34, FLAG and C-Myc. The expression cassette may include one or more linkers as described herein, for example, the linker separates the 3'CAR or PHGDH sequence from the tag.
[0123] In alternative aspects, the present disclosure relates to an expression cassette comprising a polynucleotide sequence encoding PHGDH as described herein and a separate expression cassette comprising a sequence encoding a chimeric antigen receptor (CAR) as described herein, wherein the expression cassette is adapted to be genetically modified to cells as described herein, preferably immune cells, preferably T cells. The expression cassette can be adapted to be adapted to strengthen PHGDH expression and to express CAR in cells as described herein, preferably immune cells, preferably T cells. The expression cassette can be adapted to be genetically modified to cell therapy as described herein, preferably adoptive cell therapy, preferably T cell therapy.
[0124] CAR-T is an engineered synthetic receptor that can be expressed in immune cells and functions to redirect immune cells, preferably lymphocytes, most commonly T cells, to recognize and eliminate cells expressing specific target antigens. The binding of CAR to target antigens expressed on the cell surface is independent of MHC receptors, resulting in strong T cell activation and a powerful anti-tumor response. CAR is a modular synthetic receptor whose structure has been well characterized in the art. CAR consists of the following three main components: (1) an extracellular target antigen binding domain (ABD), (2) a transmembrane domain, and (3) one or more intracellular signaling domains. CAR may also include a hinge region extending the ABD from the transmembrane domain.
[0125] Antigen binding domain (ABD) (or extracellular domain) is the part of CAR that gives target antigen specificity.Usually, the antigen binding domain is derived from the variable heavy chain (VH) and light chain (VL) of monoclonal antibody, connected via flexible linker to form single chain variable fragment (scFv).
[0126] The transmembrane domain connects the ABD and the intracellular signaling domain and functions to anchor the CAR to the cell membrane. The transmembrane domain is usually derived from a transmembrane receptor protein. Most transmembrane domains are derived from natural proteins, including CD3ζ, CD4, CD8α, or CD28, but the transmembrane domain can also be derived from a synthetic source.
[0127] The intracellular signaling domain (or cytoplasmic signaling domain) is responsible for activating at least one of the normal effector functions of the immune cells expressing CAR. "Effector function" refers to the specialized function of the cell. For example, the effector function of T cells may be cytolytic activity or auxiliary activity, including the secretion of cytokines. CAR may include one or more intracellular signaling domains (e.g., a second-generation CAR may include two intracellular signaling domains; and a third-generation CAR may include three intracellular signaling domains), wherein cell activation is mediated by the following different categories of intracellular signaling domains: at least one intracellular signaling domain (primary intracellular signaling domain) that initiates antigen-dependent primary activation through TCR and one or more intracellular signaling domains (co-stimulatory intracellular signaling domains) that act in an antigen-independent manner to provide secondary or costimulatory signals.
[0128] The primary intracellular signaling domain regulates the primary activation of the TCR complex in a stimulatory or inhibitory manner. The primary intracellular signaling domain that acts in a stimulatory manner may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif (ITAM).
[0129] The co-stimulatory intracellular signaling domain refers to the portion of the intracellular domain of the CAR that contains a co-stimulatory molecule. Co-stimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are necessary for lymphocytes to effectively respond to antigens.
[0130] The expression cassette as described herein may comprise a sequence encoding a CAR comprising one or more ABDs as described herein, a transmembrane domain as described herein, and one or more intracellular signaling domains as described herein, preferably two or more intracellular signaling domains.
[0131] The one or more ABDs can be any domains known in the art that can specifically bind to a specific antigen. In a preferred aspect, ABD is an antibody or an antigen-binding fragment of an antibody that specifically binds to an antigen, preferably ScFV. In a preferred aspect, the antigen can be a cancer-associated antigen, preferably BCMA, CD19, CD22, CD30, CD33, CD56, CD123, CEA, EBV-associated antigens, EGFR, GD2, GPC3, HER2, HPV-associated antigens, MAGE antigens, mesothelin, MUC-1, NY-ESO-1, PSCA, PSMA, ROR1, WT1, and one or more of claudin 18.2; preferably one or more of CD19, BCMA, CD30, CD33, CD123, or FLT3. In one aspect, CAR may include more than one ABD as described herein, such as two or more ABDs. In one aspect, CAR can be a bispecific CAR comprising two or more ABDs, wherein one ABD specifically binds to an antigen as described herein and one ABD specifically binds to a different antigen as described herein; preferably a bispecific CAR comprising a CD19 ABD and a CD22 ABD; a bispecific CAR comprising a CD19 ABD and a CD20 ABD; a bispecific CAR comprising a CD19 ABD and a BCMA ABD; a bispecific CAR comprising a HER2 ABD and an IL13Ra2 ABD; or a bispecific CAR comprising a HER2 ABD and a MUC1 ABD. Approved CAR T cell therapies include CARs comprising an ABD that specifically binds to CD19 or BCMA. In a preferred aspect, the antigen is CD19 or BCMA. The expression cassette as described herein may include a sequence encoding a CD19 ScFV, preferably ScFV FM63 (reference), or a sequence encoding a BCMA ScFV. In another aspect, the antigen may be a viral antigen. The viral antigen may be any component of a viral particle that can be accessed by a CAR, such as an antigen that forms a portion of the surface and / or protein capsid of a virus. Preferably, the viral antigen recognized by CAR is an antigen derived from human immunodeficiency virus (HIV), adenovirus, polyomavirus, influenza virus, hepatitis B or human herpes virus, in particular human herpes virus, wherein the human herpes virus is cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), varicella-zoster virus (VZV) or human herpes virus 8 (HHV8), preferably the viral antigen is an EBV antigen.
[0132] The membrane-spanning (TM) domain can be derived from a natural source or from a synthetic source. When the source is natural, the domain can be derived from any membrane-bound protein or a membrane-spanning protein. The membrane-spanning region can at least comprise a membrane-spanning region or a portion thereof of an α, β or ζ chain of a T cell receptor, CD28, CD8, CD3ε, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. Alternatively, the membrane-spanning domain can be synthetic, in which case the membrane-spanning domain will mainly comprise hydrophobic residues, such as leucine and valine. Preferably, a triplet of phenylalanine, tryptophan and valine will be present at each end of the synthetic membrane-spanning domain.
[0133] In a preferred aspect, the transmembrane region is derived from CD8, optionally with the hinge region present therein.
[0134] The primary intracellular signaling domain can be selected from the intracellular signaling domain derived from CD3ζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CDS, CD22, CD79a, CD79b and CD66d. In a preferred aspect, the intracellular signaling domain of the CAR described herein includes an intracellular signaling domain derived from CD3ζ.
[0135] The co-stimulatory intracellular signaling domain can be selected from one or more of CD27, CD28, 4-1BB (CD 137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, MYD88, B7-H3, and a ligand that specifically binds to CD83. In a preferred aspect, the co-stimulatory intracellular signaling domain is CD28 or 4-1BB or a combination thereof.
[0136] A CAR as described herein may comprise a short oligomeric or polypeptide linker, preferably between 2 and 10 amino acids in length, forming a bond between the transmembrane domain and the intracellular signaling domain of the CAR, preferably a glycine-serine doublet linker.
[0137] In a preferred aspect, the expression cassette according to the present disclosure comprises a polynucleotide sequence encoding a promoter, preferably a polynucleotide sequence of an EF-1α promoter; a polynucleotide sequence encoding a CAR, preferably wherein the CAR comprises CD19ScFV, a CD8 hinge and CD8 TM region, a 4-1BB co-stimulatory region, a CD3ζ primary intracellular region; a polynucleotide sequence encoding a P2A self-cleaving linker; a polynucleotide sequence encoding a PHGDH, the polynucleotide sequence preferably comprising SEQ ID NO: 4 or a sequence having 95% identity with SEQ ID NO: 4 and encoding a PHGDH having RNA binding activity.
[0138] In some aspects, the present disclosure provides a vector comprising any polynucleotide sequence described herein or any expression cassette described herein. A vector comprising an expression cassette may be referred to as an expression vector.
[0139] Any vector system known in the art and as described herein can be used to introduce a polynucleotide sequence as described herein into a cell, preferably a mammalian cell, preferably for expressing a polynucleotide sequence encoding PHGDH as described herein in a cell, preferably an immune cell, preferably a T cell. For example, the vector can comprise a single-stranded or double-stranded nucleic acid, such as a single-stranded or double-stranded DNA. For example, the vector can be a DNA, such as a naked DNA, such as a plasmid, a mini-circle, etc. The vector can comprise a single-stranded or double-stranded RNA, including a modified form of RNA. In another example, the vector can be an RNA, such as an mRNA or a modified mRNA. Methods for transfecting cells with mRNA include electroporation, chemical transfection methods, such as lipofection or cationic polymers. As another example, the gene delivery vector can be a viral vector derived from a virus, such as an adenovirus, an adeno-associated virus, LV, a herpes virus, an alpha virus, or a retrovirus, such as Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), foamy virus, Friend murine leukemia virus, Murine Stem Cell Virus (MSCV), or Rous Sarcoma Virus (RSV). Although embodiments covering the use of LV are described in more detail below, it is expected that the skilled artisan will recognize that similar knowledge and skills in the art can also be applied to non-LV gene therapy vectors. Specifically, viral vectors include, for example, retroviral vectors for stable gene expression in target cells; and adenoviral or adeno-associated viral vectors for transient gene expression in target cells. Retroviral vectors include gamma retroviruses, lentiviruses, NILV-S / MAR vectors (using non-integrating lentiviral (NILV) vectors containing scaffold / matrix attachment region (S / MAR) elements). Non-viral vectors include mRNA vectors, transposons, and lipid nanoparticles.The vector may also contain sequences encoding proteins for expressing a transgene or silencing a target gene, such as transposases (e.g., sleeping beauty, piggyBac); and endonucleases, such as zinc finger nucleases, TALEN, CRISPR / Cas9. Methods for vector and transgene delivery include electroporation, lipid nanoparticles, nuclear transfection, hydrodynamic delivery, and cell penetrating peptides.
[0140] Gamma-retrovirus and lentivirus are most commonly used to make CAR T cells due to their high transduction efficiency. In a preferred aspect, the vector as described herein is a retroviral vector, preferably a lentiviral vector (LV) comprising a polynucleotide encoding PHGDH as described herein, preferably a LV expression vector comprising an expression cassette, the expression cassette comprising a polynucleotide encoding PHGDH as described herein. The LV expression vector can be a self-limiting LV expression vector, a self-inactivating LV expression vector, or a non-integrating LV expression vector.
[0141] As used herein, "lentivirus" refers to the genus of the Retroviridae family. Slow viruses are unique among retroviruses because they are able to infect non-dividing cells; they can deliver large amounts of genetic information into the DNA of host cells, so they are one of the most effective vector gene delivery methods. HIV, SIV, and FIV are all examples of slow viruses. Vectors derived from slow viruses provide a means of achieving significant levels of gene transfer in vivo. LV vectors have been well characterized and their production is known in the art.
[0142] One or more LV vectors are used to generate an LV expression vector comprising an expression cassette comprising a polynucleotide encoding a gene of interest. The following LV plasmid vectors are typically used to generate the LV expression vector: 1) a transfer plasmid comprising a polynucleotide encoding a gene of interest, 2) one or more packaging plasmids, and 3) an envelope plasmid. The LV plasmid vectors are then transfected into cells, preferably in vitro (e.g., in HEK-293 cells), to generate an LV expression vector comprising an expression cassette that can be used to transduce cells to express the gene of interest (i.e., the LV particles comprise an expression cassette that can be used to transduce cells to express the gene of interest).
[0143] The carrier as described herein can include any LV plasmid vector as described herein or their combination. The LV plasmid vector as described herein can include a transfer plasmid, and the transfer plasmid includes a polynucleotide encoding PHGDH as described herein. The transfer plasmid can be any transfer plasmid known in the art and as described herein. Preferably, the transfer plasmid is an HIV-1 replication defective transfer plasmid, preferably selected from a second generation or third generation transfer plasmid, preferably a third generation transfer plasmid, preferably selected from pLV-mcherry and pSFFV. Packaging plasmids and envelope plasmids can be selected from any plasmid known in the art and as described herein for use with transfer plasmids as described herein and based on the compatibility of the transfer plasmid. For example, a second generation transfer plasmid must be used with a second generation packaging plasmid. A third generation transfer plasmid can be used with a second generation or third generation packaging plasmid. In a preferred aspect, the packaging plasmid is a second generation packaging plasmid, preferably selected from psPAX2 or pCMVR.8.74. Envelope plasmids are interchangeable and usually encode VSV-G. In a preferred aspect, the envelope plasmid is pMD2G or pCMV.
[0144] In one aspect, the present disclosure provides a kit comprising one or more of the vectors described herein, preferably a LV vector as described herein, preferably a transfer plasmid as described herein, and one or more LV vectors as described herein, wherein the LV vector is selected from one or more packaging plasmids as described herein and / or envelope plasmids as described herein.
[0145] In a preferred aspect, the present disclosure relates to a vector as described herein, preferably a LV expression vector, comprising an expression cassette comprising a polynucleotide sequence encoding PHGDH and a polynucleotide sequence encoding CAR as described herein.
[0146] In an alternative aspect, the present disclosure relates to a vector as described herein, preferably a LV expression vector, comprising an expression cassette containing a polynucleotide sequence encoding PHGDH as described herein; and a separate vector comprising an expression cassette containing a polynucleotide sequence encoding CAR as described herein.
[0147] Vectors as disclosed herein can also be used to introduce polynucleotide sequences or polypeptides that increase the expression of endogenous PHGDH. For example, the activity of one or more endogenous promoters and / or enhancer regions associated with the PHGDH gene can be increased by methods known in the art. The silencing of endogenous PHGDH expression can be prevented or reduced, for example, by introducing polynucleotide sequences encoding siRNA, antisense, ribozymes, shRNA, methylation of CpG nucleotides of the PHGDH gene in the promoter region, and non-coding RNA-related gene silencing.
[0148] The present disclosure also provides a cell, such as one or more cells, comprising any of the polynucleotide sequences, expression cassettes, vectors and / or expression vectors disclosed herein. The cell can be any cell that can be used for recombinant genetic technology, such as a cell for preparing a polynucleotide sequence, expression cassette, vector, expression vector and / or cell as described herein. In a preferred aspect, the cell can be any cell for producing an expression vector, preferably an LV expression vector, the expression vector comprising an expression cassette that can be used to transduce cells to express PHGDH (i.e., LV particles comprising an expression cassette that can be used to transduce cells to express PHGDH). The cell can be selected from mammalian cells (e.g., 293 cells), insect cells (e.g., SF9 cells), microorganisms and yeast. The cell can be a packaging cell that stably maintains LV vector genes, or a production cell that stably maintains and packages LV vector genomes. Exemplary packaging and production cells are derived from SF-9, 293, A549 or HeLa cells. LV vectors can be purified and formulated using standard techniques known in the art. Cells can be transduced with a viral vector comprising an expression cassette disclosed herein, or can have an expression cassette disclosed herein integrated into the genome of the cell. In certain embodiments, the cell is a cell used to produce a viral gene delivery vector (e.g., a LV particle containing an expression cassette that can be used to transduce cells to express PHGDH). In other embodiments, the cell is any cell that can be used for regenerative medicine, such as a cell therapy as described herein. Suitably, the cell is used for delivery to a subject.
[0149] The present disclosure also provides a composition comprising any one of the polynucleotide sequences, expression cassettes, vectors, expression vectors and / or cells disclosed herein. In a preferred aspect, the composition may be a pharmaceutical composition that appropriately comprises one or more pharmaceutically acceptable carriers, diluents and / or excipients. The composition may comprise a buffer, such as neutral buffered saline, phosphate buffered saline, etc.; a carbohydrate, such as glucose, mannose, sucrose or dextran, mannitol; a protein; a polypeptide or an amino acid (e.g., glycine); an antioxidant; a chelating agent, such as EDTA or glutathione; an adjuvant (e.g., aluminum hydroxide); and a preservative.
[0150] The polynucleotides, expression cassettes, vectors and compositions disclosed herein can be used in methods for strengthening the expression of PHGDH in cells. The polynucleotides, expression cassettes, vectors and compositions can be used in methods for expressing PHGDH transgenes in cells as disclosed herein. In one aspect, the present disclosure provides a method for producing cells genetically engineered to strengthen the expression of PHGDH, the method comprising contacting one or more cells with polynucleotides, expression cassettes, vectors or compositions as disclosed herein. The method can be a research method, such as a method for determining the effect of PHGDH on cell viability and / or function, or a medical method, such as a medical method for treating or preventing a disease or condition as disclosed herein or for preparing a cell or composition as disclosed herein for treating or preventing a disease or condition as disclosed herein. In some embodiments, contact occurs in vitro or ex vivo. In some aspects, contact occurs in vivo, that is, polynucleotides, expression cassettes, vectors or compositions as disclosed herein can be applied to a subject. In preferred aspects, contact occurs in vitro or ex vivo.
[0151] In a preferred aspect, the one or more cells may be any cell that can be used in regenerative medicine, preferably a cell therapy as disclosed herein, preferably an adoptive cell therapy, preferably a CAR T cell therapy. In this regard, the cell, preferably a cell genetically engineered to enhance PHGDH expression, or a composition comprising such a cell, may be administered to a subject in need thereof. In a preferred aspect, the one or more cells are immune cells, preferably lymphocytes, preferably T cells, preferably CD3 + cells, preferably CD8 + T cells and / or CD4 + T cells, such as CD8 + T cells and CD4 + A large number of T cells, including T cells.
[0152] The cells can be obtained from a subject. In a preferred aspect, the cells can be obtained from a subject to be treated by cell therapy (autologous), for example, the cells can be obtained from a subject before cell therapy. In other aspects, cells can be obtained from a subject other than a subject to be treated by cell therapy (e.g., allogeneic from a donor). Preferably, the cells are mammalian cells, preferably human cells.
[0153] Cells as described herein can be obtained from any source from a subject using methods known in the art. In preferred aspects, immune cells as disclosed herein, preferably one or more lymphocytes, can be obtained from a subject from a variety of sources, including peripheral blood, mononuclear cells, bone marrow, lymph node tissue, blood, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue and tumor. Any type of lymphocyte available in the art and described herein can be used. In general, those skilled in the art know the method of separating a certain type of lymphocyte from a suitable source. In preferred aspects, the method includes obtaining peripheral blood mononuclear cells (PBMC) from a subject, preferably from blood, by methods known in the art. Preferably, PBMC is unmobilized. PBMC can be obtained by methods known in the art, for example, by density gradient centrifugation scheme (Lymphoprep; Fresenius Kabi) through Ficoll TM Separate or obtain from a blood sample of a subject by apheresis, preferably leukapheresis. The cells obtained by apheresis can be washed to remove the plasma fraction and placed in an appropriate buffer or culture medium for subsequent processing steps. In a preferred aspect, T cells can be obtained from PBMC by methods known in the art.
[0154] Ex vivo or in vitro cell therapy methods are known in the art and include one or more of isolating, enriching, activating and expanding cells. After obtaining cells from a subject and / or before administering the cells to a subject, one or more ex vivo cell therapy methods may be performed.
[0155] Cells can be isolated and / or enriched by positive or negative selection techniques known in the art and as described herein, for example using density gradient centrifugation and / or magnetic beads. In the methods described herein, separation and / or enrichment can occur before or after contacting one or more cells with a polynucleotide, expression cassette, vector or composition as disclosed herein. Lymphocytes have been well characterized, and it is known in the art which surface antigens can be presented on different types of lymphocytes. One skilled in the art is able to select conditions for positive or negative selection that allow enrichment or isolation of a particular type of cell, in particular a particular type of lymphocyte. In addition, commercial kits can be readily used to enrich and / or isolate specific cells, in particular lymphocytes. In a preferred aspect, the method comprises isolating and / or enriching lymphocyte subsets, such as CD3 + 、CD28 + 、CD4 + 、CD8 + 、CD45RA + and CD45RO + T cells, CD16+ and CD56 + NK cells or CD3 + 、CD56 + and CD161 + NKT cells; preferably CD3 + cells, preferably CD8 + cells and / or CD4 + cells, preferably CD8 + cell.
[0156] Cells can be activated and / or expanded by techniques known in the art and as described herein before being administered to a subject, for example using antibody-coated microbeads, such as anti-CD3 / anti-CD28-coated microbeads. In the methods described herein, activation and / or expansion can occur before or after contacting one or more cells with a polynucleotide, expression cassette, vector or composition as disclosed herein. Activation and / or expansion can occur before or after separation and / or enrichment. Cells can also be activated and / or expanded after being administered to a subject by techniques known in the art.
[0157] NK cells described herein can be activated by culturing cells in an appropriate culture medium (e.g., minimal essential medium or RPMI culture medium 1640 or X-vivo 15, (Lonza), CellGro culture medium (Cellgenix), IMDM (Gibco)), which may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine, human or horse serum) supplemented with IL-15 and / or IL-12 and / or IL-18. NK cell activation can also be accomplished by supplementing the culture medium with IL-2. NK cell activation can be increased by adding feeder cell lines to the culture.
[0158] T cells described herein can be activated by contacting with a surface of a ligand attached with a medicament that stimulates CD3 / TCR complex-related signals and a co-stimulatory molecule on the T cell surface. Specifically, T cell groups can be contacted with anti-CD3 antibodies or their antigen-binding fragments, or anti-CD2 antibodies fixed on the surface, or by contacting with a protein kinase C activator (e.g., bryostatin) bound to a calcium ion carrier. In order to costimulate the auxiliary molecules on the surface of T cells, a ligand that binds to the auxiliary molecule can be used. For example, T cell groups can be contacted with anti-CD3 antibodies and anti-CD28 antibodies under conditions suitable for stimulating T cell proliferation.
[0159] In a preferred aspect, the method as described herein comprises obtaining cells from a subject by leukapheresis of unmobilized peripheral blood mononuclear cells; ex vivo enriching and selecting T cells expressing CD3, preferably T cells expressing CD8 and CD4; and activating T cells using anti-CD3 and / or anti-CD28 antibodies in the presence of IL2.
[0160] The present disclosure provides one or more cells as disclosed herein transduced with a vector comprising a polynucleotide encoding PHGDH and optionally a polynucleotide encoding CAR as disclosed herein; or one or more cells as disclosed herein transduced with a vector comprising a polynucleotide encoding PHGDH and optionally a separate vector comprising a polynucleotide encoding CAR as disclosed herein. The one or more cells may include a control switch, such as a suicide switch, an endogenous switch, or an exogenous switch. Therefore, the present invention provides a method of transducing one or more cells as disclosed herein with a vector comprising a polynucleotide encoding PHGDH and optionally a polynucleotide encoding CAR as disclosed herein; or a vector comprising a polynucleotide encoding PHGDH and a separate vector comprising a polynucleotide encoding CAR as disclosed herein. In various aspects, the method as described herein may include separation and / or enrichment after contacting one or more cells with a polynucleotide, expression cassette, vector, or composition as disclosed herein. In one aspect, the method comprises isolating and / or enriching cells transduced with a vector comprising a polynucleotide encoding PHGDH and, optionally, a polynucleotide encoding CAR as disclosed herein; or isolating and / or enriching cells transduced with a vector comprising a polynucleotide encoding PHGDH and, optionally, a separate vector comprising a polynucleotide encoding CAR as disclosed herein.
[0161] As used herein, the term "transduction" or "transfection" refers to the process of transferring or introducing exogenous nucleic acid into a host cell. A "transfected" or "transduced" cell is a cell that has been transfected or transduced with exogenous nucleic acid.
[0162] The present disclosure also provides a method of treatment, the method comprising administering to a subject in need any cell as disclosed herein or any of the compositions, polynucleotide sequences, expression cassettes, vectors and / or expression vectors disclosed herein. In a preferred aspect, the method of treatment comprises any treatment requiring enhanced cell persistence, such as any treatment in the field of regenerative medicine, preferably a cell therapy as described herein, preferably an adoptive cell therapy as described herein.
[0163] The present disclosure also provides any cell as disclosed herein or any of the compositions, polynucleotide sequences, expression cassettes, vectors and / or expression vectors disclosed herein, for use in any of the methods described herein, in particular for use in any of the therapeutic methods described herein.
[0164] The present disclosure also provides use of any cell as disclosed herein or any of the compositions, polynucleotide sequences, expression cassettes, vectors and / or expression vectors disclosed herein in the manufacture of a medicament for use in any method described herein, in particular for use in the therapeutic methods as described herein.
[0165] The terms "treatment" and the like as used herein generally mean obtaining the desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or condition, and / or may be therapeutic in terms of partially or completely curing a disease or condition and / or side effects attributable to the disease. "Treatment" as used herein encompasses any treatment of a disease or condition in a mammal, preferably a human, and includes: improving a disease, illness or condition (i.e., slowing or preventing or reducing the development of at least one clinical symptom of a disease, illness or condition or its clinical symptoms); alleviating or improving at least one physical parameter, including those that may not be discernible by the patient; regulating a disease, illness or condition, whether physically (e.g., stabilizing discernible symptoms), physiologically (e.g., stabilizing physical parameters) or both; or preventing or delaying the onset, development or progression of a disease, illness or condition or one or more clinical symptoms thereof.
[0166] As used herein, the phrase "ameliorating at least one symptom of" refers to reducing one or more symptoms of a disease or condition in the subject being treated. The disease or condition being treated may be selected from any of the diseases or conditions disclosed herein.
[0167] In a preferred aspect, the present disclosure provides an improved cell therapy and polynucleotides, expression vectors and methods for preparing and using the same. Specifically, the present disclosure provides an improved cell therapy, preferably any cell therapy in the cell therapy disclosed herein, the cell therapy comprising one or more cells as described herein, the cells being transplanted into a subject with a disease or condition to treat the disease or condition, wherein the present disclosure improves the persistence and / or survival rate of transplanted cells. In a preferred aspect, the present disclosure provides an improved adoptive cell therapy, wherein the one or more transplanted cells are immune cells, preferably lymphocytes, preferably T cells as described herein, and the cells optionally include one or more CARs as described herein. In a preferred aspect, the present disclosure provides an improved CAR T cell therapy, particularly CAR T cell therapy as described herein. In a preferred aspect, the method for treating any of the diseases or conditions as described herein may include administering any of the cells or pharmaceutical compositions as described herein to a subject in need.
[0168] Several cell therapies have been approved by regulatory authorities for the treatment of various diseases and conditions. CAR T cell therapy has been approved for the treatment of diseases including cancer, particularly hematological cancers or blood cancers. Hematopoietic progenitor cell (HPC) transplantation (stem cell or bone marrow transplantation, also known as HSCT) is approved for the treatment of diseases including amyloidosis, germ cell tumors (e.g., testicular cancer), acute leukemia, megakaryocyte deficiency or congenital thrombocytopenia, aplastic anemia or refractory anemia, chronic lymphocytic leukemia, familial erythrophagocytic lymphohistiocytosis, myelodysplastic syndrome of another myelodysplastic disorder, osteosclerosis, paroxysmal nocturnal hemoglobinuria and Wiskott-Aldrich syndrome. HSCT can be autologous or allogeneic, such as salvage allogeneic HSCT. Other approved cell therapies include the treatment of melanoma, prostate cancer, mucogingival disorders, retinal disorders and diseases, cartilage defects, athymus, burns and muscle atrophy.
[0169] Approved CAR T-cell therapies include:
[0170] Idecabtagene vicleucel (trade name: ABECMA; STN: BLA 125736; Celgene Corporation) is approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy including immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies.
[0171] Lisocabtagene maraleucel (trade name: BREYANZI; STN# BLA 125714; Juno Therapeutics, Inc.) is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma.
[0172] Tisagenlecleucel (trade name: KYMRIAH; STN: 125646; Novartis) is approved for the treatment of pediatric and young adult patients (ages 3-25 years) with refractory or second or later relapsed B-cell precursor acute lymphoblastic leukemia (ALL). Adult patients with relapsed or refractory (r / r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL derived from follicular lymphoma.
[0173] Brexucabtagene autoleucel (TECARTUS; STN: BL 125703; Kite Pharma, Inc.) is approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). New indication for this supplement: Adult patients with relapsed or refractory (r / r) B-cell precursor acute lymphoblastic leukemia (ALL).
[0174] Axicabtagene ciloleucel (trade name: YESCARTA; STN: BL 125643; Kite Pharma Inc.) is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL derived from follicular lymphoma, after two or more lines of systemic therapy. Axicabtagene ciloleucel is not indicated for the treatment of patients with primary central nervous system lymphoma.
[0175] The terms "patient," "subject," "individual," and the like are used interchangeably herein and refer to any animal or cell thereof suitable for the methods described herein, whether in vitro or in situ. In certain non-limiting embodiments, the patient, subject, or individual is a human.
[0176] In preferred aspects, the method of treating a disease or condition as described herein may include treating cancer. As used herein, the term "cancer" refers to a disease characterized by the rapid and uncontrolled growth of abnormal cells. Cancer cells can spread locally or to other parts of the body through the bloodstream and lymphatic system.
[0177] Hematological cancers are cancers of the blood or bone marrow. Examples of hematological (or blood-borne) cancers include leukemias, including acute leukemias (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute myeloid leukemia, and myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, and erythroleukemia), chronic leukemias (e.g., chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphomas, Hodgkin's disease, non-Hodgkin's lymphomas (indolent and advanced forms), mantle cell lymphomas, multiple myeloma, Warren's macroglobulinemia, heavy chain disease, myelodysplastic syndrome, hairy cell leukemia, and myelodysplasia.
[0178] Solid tumors are abnormal tissue masses that usually do not contain cysts or fluid areas. Solid tumors can be benign or malignant. Different types of solid tumors are named according to the type of cells that form them, such as sarcomas, carcinomas, and lymphomas. Examples of solid tumors include fibrosarcomas, myosarcomas, liposarcoma, chondrosarcomas, osteosarcomas and other sarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, lymphoid malignancies, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct cancer, Choriocarcinoma, Wilms' tumor, cervical cancer, testicular tumors, seminoma, bladder cancer, melanoma, and CNS tumors (e.g., gliomas (e.g., brain stem gliomas and mixed gliomas), glioblastomas (also known as glioblastoma multiforme), astrocytomas, CNS lymphomas, germ cell tumors, medulloblastomas, schwannomas, craniopharyngiomas, ependymomas, pinealomas, hemangioblastomas, acoustic neuromas, oligodendrogliomas, meningiomas, neuroblastomas, retinoblastomas, and brain metastases).
[0179] The cancer may be a hematological cancer as described herein, preferably selected from acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma and mantle cell lymphoma; or a solid tumor, preferably selected from colon cancer, breast cancer, pancreatic cancer, ovarian cancer, hepatocellular carcinoma, lung cancer, neuroblastoma, glioblastoma or sarcoma.
[0180] In a preferred aspect, the method for treating a disease or condition as described herein may include administering to a subject any of the cells or pharmaceutical compositions as described herein, particularly genetically engineered to enhance the expression of PHGDH as described herein, preferably T cells, preferably wherein the cells comprise CAR or modified TCR as disclosed herein. In one aspect, CAR or TCR may comprise one or more antigen binding domains (ABDs), the ABDs specifically binding to BCMA, CD19, CD22, CD30, CD33, CD56, CD123, CEA, EBV-related antigens, EGFR, GD2, GPC3, HER2, HPV-related antigens, MAGE antigens, mesothelin, MUC-1, NY-ESO-1, PSCA, PSMA, ROR1, WT1, and one or more of claudin 18.2; preferably one or more of CD19, BCMA, CD30, CD33, CD123, or FLT3; preferably an ABD specifically binding to CD19 or BCMA.
[0181] In one aspect, the CAR or TCR may comprise a CD19 ABD and the method comprises treating a cancer derived from a B cell, preferably a B cell lymphoma, acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL). In preferred aspects, the methods include treating adult patients with relapsed or refractory (r / r) large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), not otherwise specified (DLBCL), high-grade B-cell lymphoma and DLBCL derived from follicular lymphoma, DLBCL derived from indolent lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma; pediatric and young adult patients (ages 3-25 years) with B-cell precursor acute lymphoblastic leukemia (ALL) that may be refractory or in second or subsequent relapse; adult patients with relapsed or refractory mantle cell lymphoma (MCL); adult patients with r / r ALL.
[0182] In another aspect, the CAR or TCR may comprise a BCMA ABD, and the method comprises treating a blood cancer, preferably multiple myeloma. In a preferred aspect, the method comprises treating an adult patient with relapsed or refractory multiple myeloma, such as an adult patient with relapsed or refractory multiple myeloma after four or more prior lines of therapy comprising an immunomodulator, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
[0183] In one aspect, the method for treating a disease or condition as described herein may include treating an infection in a subject, such as a viral infection or a fungal infection, preferably a viral infection. In a preferred aspect, the method for treating a disease or condition as described herein may include administering any of the cells or pharmaceutical compositions as described herein, particularly genetically engineered to enhance the expression of PHGDH as described herein, preferably T cells, preferably wherein the cells comprise a CAR or a modified TCR as disclosed herein. In one aspect, a CAR or TCR may comprise one or more ABDs that specifically bind to one or more viral antigens. A viral antigen may be any component of a viral particle that can be accessed by a CAR or TCR, such as an antigen that forms a portion of the surface and / or protein capsid of a virus. Preferably, the viral antigen is an antigen derived from human immunodeficiency virus (HIV), adenovirus, polyomavirus, influenza virus, hepatitis B virus (HBV) or human herpes virus, in particular wherein the human herpes virus is cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), varicella-zoster virus (VZV) or human herpes virus 8 (HHV8).
[0184] In preferred aspects, the method for treating a disease or condition as described herein may include administering to a subject any of the cells as described herein or a pharmaceutical composition comprising the cells as part of a cell therapy. The cells as described herein or any of the pharmaceutical compositions comprising the cells are applied to a subject as part of a cell therapy and may be referred to herein as cell transplantation or grafting. Specifically, cells (preferably immune cells, preferably T cells, preferably wherein the cells comprise CAR or modified TCR as disclosed herein) genetically engineered to enhance PHGDH expression as described herein may be applied to a subject as part of a cell therapy. Cells may be autologous or allogeneic, preferably autologous. The method for treating a disease or condition may include obtaining cells from a subject, for example, the method may include obtaining PBMCs from a subject by leukapheresis and PBMC separation of non-mobilized PBMCs as known in the art and as described herein. The method may further include any of the ex vivo or in vitro cell therapy methods known in the art and described herein, including one or more of separation, enrichment, activation and amplification cells as disclosed herein. The method may include methods of activating and / or expanding cells in vivo by methods known in the art and as disclosed herein. After obtaining the cells from the subject and / or before administering the cells to the subject, one or more ex vivo or in vitro cell therapy methods may be performed. In a preferred aspect, the method includes isolating and / or enriching lymphocyte subsets, preferably T cells, preferably CD3 + cells, preferably CD8 + and / or CD4 + cells, preferably CD8 + In a preferred aspect, the method comprises activating cells, preferably T cells, using anti-CD3 and / or anti-CD28 antibodies.
[0185] Methods for treating diseases or conditions as described herein may include administering any cell as disclosed herein or any of the compositions, polynucleotide sequences, expression cassettes, vectors, and / or expression vectors disclosed herein in combination with one or more other therapeutic agents or treatments to a subject in need thereof. The compositions described herein may comprise an effective amount of any of the cells as disclosed herein or any of the compositions, polynucleotide sequences, expression cassettes, vectors, and / or expression vectors disclosed herein in combination with one or more other therapeutic agents or treatments. Other therapeutic agents or treatments may be selected from other known treatments for the diseases disclosed herein.
[0186] All features described herein (including any accompanying claims, abstracts and drawings) and / or all steps of any method so disclosed may be combined with any of the above aspects in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. In particular, any of the active agents and compositions described herein may be used in any of the described methods of treatment. Any and all such combinations are expressly contemplated to form part of the present invention.
[0187] Example
[0188] Example 1 - Metabolic pruning is a hallmark of memory T cell differentiation
[0189] This study focused on comparing CD8 + T NV and T EM Specifically, CD8 + T cells were sorted by flow cytometry followed by RNAseq and proteomics ( Figure 1A ). 'Cellular metabolic process' is CD8 + T EM Contrast T NV The most abundant GO terms among the downregulated RNA species in cells ( Figure 1B ). At the transcript and protein levels, PHGDH is a T EM The most downregulated metabolic transcript in the cells and one of the most differentially expressed proteins overall ( Figure 1C ). CD8 + T EM and T NV The differential expression of PHGDH between the two groups was confirmed by Western blotting ( Figure 1D ).
[0190] Upon activation, i.e. in primary effector cells, naive murine T cells induce components of the serine synthesis pathway (SSP) ( Figure 1E ). This led us to test the potential of secondary effector cells, namely those derived from CD8 + T CM and T EM In the cells of T cells, the expression of PHGDH, PSAT1 and PSPH was also upregulated. NV Compared with T cells EM Cells and T CM Only slight induction of PHGDH was detected in the cells ( Figure 1F ). NV In cells, the abundance of PHGDH further increased ( Figure 1F ).
[0191] Given that CD8 + T CM and T EM Since T cells do not express PHGDH, we reasoned that extracellular serine might also selectively affect the proliferation capacity of these cells. CM and T EM cannot proliferate, and T NV Cell proliferation is less affected ( Figure 1G ).
[0192] These data confirm that CD8 + T EM This trait was maintained when these cells were restimulated and became secondary effectors. EM The cells are strictly dependent on exogenous serine for proliferation and are therefore serine auxotrophic.
[0193] Example 2 - PHGDH is an RNA binding protein
[0194] To explore the concept of a moonlighting role for PHGDH, its structure was compared in silico to that of the atypical RNA-binding protein (RBP) GAPDH; both are NAD + Several RNA-binding domains have been proposed for GAPDH, including a Rossmann fold (a + Several similarities between the two enzymes were noted: in addition to the Rossmann fold, PHGDH also displays a positively charged substrate groove and a dimer interface with basic and aromatic residues ( Figure 2A ).
[0195] To directly explore the potential RNA binding role of PHGDH in T cells, RNA immunoprecipitation sequencing (RIPseq) experiments were performed using primary human effector T cells. KO Jurkat T cell lysates were used to verify the specificity of the PHGDH-IP antibody ( Figure 2B , left panel). In addition, to confirm the IP of PHGDH for each sample before sequencing the co-precipitated RNA, an isotype-matched antibody was used as a control ( Figure 2B , right panel). Compared with the input sample, PHGDH-IP significantly enriched 4419 transcripts, while isoform IP enriched 927 transcripts ( Figure 2C). To visualize the filtering strategy, we plotted transcripts enriched by isotype IP compared to input material versus transcripts enriched in PHGDH-IP compared to input material. RNA species that (i) were >2-fold enriched in PHGDH-IP compared to input, and (ii) were more than 2-fold enriched in PHGDH-IP when compared to isotype IP were considered to specifically interact with PHGDH. This filtering process selected 1639 protein-coding transcripts ( Figure 2D ), indicating the RNA binding characteristics of PHGDH in primary human T cells, i.e., the functional characteristics of RBPs. Since the expression of PHGDH is a hallmark of undifferentiated cells (data not shown), it is speculated that it may be related to the maintenance of survival through the RNA binding properties of PHGDH. Notably, pro-survival genes, namely BBC3, MCL1, and TP53BP2 ( Figure 2E ).
[0196] To further explore this concept, we used CRISPR / Cas9 to generate primary human T cells from NV Cell design PHGDH knockout experiment ( Figure 2F To ensure that loss of PHGDH affected primarily the RNA binding properties of the enzyme and to prevent metabolic stress responses, experiments were performed in the presence of abundant extracellular serine. After three days of activation, PHGDH mRNA was the most downregulated transcript among the 1425 differentially expressed transcripts / genes (DEGs) ( Figure 2G ), whose smaller fold change is consistent with the post-transcriptional perturbations described for RBPs (Lu et al., 2014, Cell Rep. 9, 2330-2343; Diaz- et al., 2015, Nature Immunology. 16, 415-425; and Monzón-Casanova et al., 2020, eLife. 9, 613-28). Of these DEGs, approximately 10% (177) were also specifically pulled down in the RIPseq experiment, including RNA species encoding epigenetic modifiers (KDM3A, DOT1L, KAT2A, and KDM6B), WNT signaling components (DVL1 and Jun), and transcripts affecting survival (NFKBIA and IRF1) ( Figure 2H ).
[0197] Collectively, these data suggest that PHGDH moonlights as an RBP, and the findings are consistent with the concept that, through RNA binding, PHGDH may help regulate T cell differentiation or survival.
[0198] Example 3 - Enhanced expression of PHGDH enhances the persistence of T cells in vivo
[0199] To further explore the role of PHGDH in regulating T cell survival, we established an in vivo mouse infection model. Analysis of RNAseq data from the ImmGen Consortium (immgen.org) showed that mouse CD8 + The expression pattern of PHGDH among naive, central memory and effector memory T cells is similar to that of human CD8 + T cells are similar ( Figure 3A ). Mouse T cells were further analyzed by Western blotting and FACS. NV and T EM PHGDH expression levels in CD8 T cells. These experiments confirmed that PHGDH expression was reduced in memory cells ( Figure 3B To test the in vivo relevance, ovalbumin-specific CD8+ T cells (OT-I) overexpressing PHGDH (OE) or empty vector (EV) as a control were generated ( Figure 3C ). Overexpression was enhanced by retroviral transduction. Plasmid constructs were: MigR1-PHGDH-IRES-EGFP (OE-PHGDH) and MigR1-IRES-EGFP (EV) vectors (addgene).
[0200] To examine whether overexpression of PHGDH affects OT-I CD8 + Expansion or survival of T cells, adoptive transfer of OE or EV OT-I cells into C57BL / 6 recipients ( Figure 3D ). One day after transfer, recipient mice were infected with LmOVA and the expansion of transferred T cells in the blood was tracked. At the peak of expansion (7 dpi), comparable levels of OE and EV OT-I cells were detected ( Figure 3E However, OE-PHGDH OT-I T cells did not contract as much as control cells, resulting in higher frequencies at 14 dpi, 21 dpi, 28 dpi, and 35 dpi ( Figure 3E ).
[0201] To dissect whether the canonical or latent mRNA binding capacity of PHGDH was responsible for the observed phenotype, we generated OT-I T cells overexpressing the wild-type (OE-WT) or catalytically inactive (OE-CD) variant of PHGDH. OE-WT, OE-CD or EVOT-I T cells were transferred into recipients, which were then infected with LmOVA. Similar to previous experiments, the frequency of transferred cells at 7 dpi was comparable, but different numbers were generated at later time points. As before, a higher frequency of cells overexpressing PHGDH was detected, and it is noteworthy that the number of OE-CDOT-I T cells even persisted at an increased level when compared to OE-WT OT-I T cells ( Figure 3F To test whether OE-CD OT-I T cells could respond to a second stimulus, we re-stimulated recipients with LmOVA. No effect of the increased persistence on the re-expansion capacity of OE-CD OT-I cells was observed ( Figure 3G ).
[0202] These data provide evidence that preventing PHGDH silencing during the effector-to-memory transition phase can increase T cell persistence.
[0203] Example 4 - Enhanced expression of HGDH enhances T cell persistence in vitro and in vivo
[0204] Based on previous data, we reasoned that overexpression of PHGDH might improve the persistence and, thus, the therapeutic potential of human (CAR)T cells.
[0205] To further examine the role of PHGDH in regulating T cell persistence, we used CRISPR / Cas to inactivate PHGDH in human naive CD8 + PHGDH was knocked out in T cells and cells were activated with anti-CD3 / CD28 24 hours later. Knockout of PHGDH was confirmed by flow cytometry 96 hours after activation ( Figure 4A Interestingly, the frequencies of late and early apoptotic cells increased after PHGDH knockdown, whereas the frequency of viable cells decreased significantly compared with control cells ( Figure 4B , right small picture).
[0206] Then test how enhanced PHGDH expression affects the persistence of primary human T cells expressing CAR. For these experiments, a CAR T cell model targeting CD19 was used. A large number of T cells were lentivirally transduced with: i) a vector encoding CD19CAR and mCherry (CD19CAR), or ii) a vector encoding CD19 CAR and mCherry and a vector encoding a catalytically inactive variant of PHGDH and GFP (CD19 CAR_PHGDH (CD)). In order to obtain a pure CAR T cell population, cells were sorted according to mCherry and GFP expression ( Figure 4C , left panel). Persistence was assessed in vitro under non-activating conditions in the presence of IL-2. Compared with cells expressing only CAR, the number of CD19 CAR_PHGDH (CD) cells was significantly enriched from day 6 to day 7 ( Figure 4C , right small picture).
[0207] We then further examined whether enhanced PHGDH expression also affected the in vivo persistence of CAR T cells. PHGDH overexpression in CAR T cells from two different donors was verified by Western blotting compared with CAR T cells ( Figure 4D To test in vivo persistence, CD19 CAR T cells or CD19 CAR_PHGDH T cells were adoptively transferred into NSG mice with established tumors ( Figure 4E , left panel). In fact, the frequency of CD19 CAR_PHGDH T cells in the spleen increased significantly 8 days after adoptive transfer compared with CD19 CAR T cells ( Figure 4E , right small picture).
[0208] Together, these data demonstrate the importance of PHGDH in regulating human T cell persistence. Furthermore, overexpression of PHGDH, either WT or CD variant, is associated with increased persistence of cell therapies, particularly T cells, both in vitro and in vivo.
[0209] Example 5: Enhanced expression of PHGDH enhances the in vivo persistence of T cells
[0210] Experiments were performed to confirm that enhanced expression of PHGDH affects the in vivo persistence of CAR T cells. CD19 CAR T cells or CD19 CAR_PHGDH T cells were adoptively transferred into NSG mice with established tumors ( Figure 5A ). At 8 days after adoptive transfer, the frequency of splenic CD19CAR_PHGDH CD3+T cells increased significantly compared with CD19 CAR T cells ( Figure 5B , left panel). CD8+ T cells were significantly enriched in most CD3+ T cell fractions ( Figure 5B, middle panel), where a similar trend was observed in the CD4+ T cell fraction ( Figure 5B , right small picture).
[0211] Example 6: Knockout of PHGDH prolongs the half-life of IRF1 mRNA
[0212] When the RIP-seq data were overlaid with the transcriptome data to identify transcripts that bind and regulate PHGDH, the analysis pinpointed the pro-apoptotic transcription factor RF1 as the leading candidate, which was selected for further analysis ( Figure 2H ).
[0213] In the case of PHGDH-depleted CD8+T NV In cells, IRF1 mRNA and protein expression increased ( Fig. 6A and Figure 6B ). This expression pattern suggests a role for PHGDH in controlling the stability of IRF1 mRNA. To test this experimentally, we performed an actinomycin D chase experiment. We used CRISPR-Cas9 to NV Cells were depleted of PHGDH, activated for 3 days, and mRNA stability was measured in the presence of actinomycin D, which was used to block transcription at the indicated time points ( Figure 6C ). Validation of CD8+ T cells by Western blotting NV Knockout of PHGDH in cells ( Fig.6D The mRNA half-life of IRF1 was shortened in cells expressing PHGDH compared to their PHGDH-depleted counterparts ( Fig. 6E ).
[0214] Example 7: PHGDH binds to IRF1 mRNA
[0215] Notably, IRF1 mRNA has multiple AU-rich elements (AREs) in the 3'UTR, which are cis-acting sequence motifs that typically reduce transcript stability when bound by RBPs (White MR et al., 2016, Wiley Interdiscip Rev RNA; 7(1):53-70). To test the direct binding of PHGDH to IRF1 mRNA, we performed microscale thermophoresis experiments using 3'UTR fragments of recombinant PHGDH and IRF1 transcripts, as shown in Figure 2. Fig. 7A As indicated in . Fragment 3 contains multiple AU-rich elements, while fragment 4 lacks AU-rich elements.
[0216] Microscale thermophoresis assays established the direct binding of PHGDH—characterized by a high response amplitude—to fragment 3 (Fg3), and thus its affinity for mRNA sequences containing AU-rich elements—classifying PHGDH as an ARE-binding protein (ARE-BP; green curve, Figure 7B and Figure 7C ). In contrast, fragment 4 (Fg4) did not bind to PHGDH characterized by a low response amplitude (red curve; Figure 7B ). The mutant version of Fg3 also hindered the binding of PHGDH (red curve; Figure 7C ).
[0217] These data demonstrate the importance of PHGDH in regulating the persistence of human (CAR) T cells. These data also demonstrate how PHGDH acts as an RBP to regulate the stability of transcripts involved in T cell survival.
[0218] method
[0219] Healthy blood donor
[0220] Blood samples were obtained as buffy coats from healthy female and male donors (16-65 years old) after written consent (Blood donation center, University Hospital Basel).
[0221] Human cell isolation
[0222] Peripheral blood mononuclear cells (PBMCs) were isolated from healthy female and male donors by standard density gradient centrifugation protocol (#1114547, Lymphoprep Fresenius Kabi). + CD8 was enriched by positive selection using beads (#130-045-201, Miltenyi Biotec) + T cells were cultured and rested overnight in R10 FBS before FACS sorting (see below).
[0223] Human T cell activation
[0224] Human CD8 + T cell activation was performed using in-house generated anti-CD3 / anti-CD28 coated microbeads as previously described 1,2 Unless otherwise stated, all T cell activations were performed using a 2:1 beads to cells ratio and occurred in flat-bottom 96-well plates (2.5×105 cells / well; 5×105 beads / well).
[0225] Flow cytometry
[0226] Cell proliferation
[0227] Cells were loaded with cell proliferation dye CFSE (1 μM, Molecular Probes, USA) before activation + / - serine and seeded in 96-well plates. CFSE dilution was analyzed by flow cytometry 5 days after stimulation. Before sample collection, a fixable live-dead cell stain (Fixable Viability Dye, eBioscience or Zombie Aqua, Biolegend) was used to exclude dead cells.
[0228] Viability and Annexin V staining
[0229] Cells were harvested and washed once with PBS and then stained with AquaZombie Fixable Viability Dye (BioLegend) and Annexin V (ThermoFisher) in Annexin Binding Buffer for 15 minutes at room temperature. The staining was quenched with Annexin Binding Buffer or FACS Buffer and cells were analyzed directly by flow cytometry or washed before further intracellular staining.
[0230] Intracellular staining
[0231] After staining the cells with Aqua Zombie and Annexin V, the cells were fixed and permeabilized using intracellular fixation and permeabilization buffer (ThermoFisher) according to the manufacturer's instructions. The cells were then stained with anti-PHGDH (#66350, D8F30, Cell Signaling) diluted in permeabilization buffer on ice for 45 minutes and then incubated with anti-rabbit Alexa Fluor 594 (ThermoFisher) on ice for 30 minutes. Prior to sample collection, the cells were washed twice with permeabilization buffer and resuspended in FACS buffer.
[0232] Unless otherwise stated, all flow data were acquired on a CytoFLEX flow cytometer (Beckman Coulter) and analyzed using Flowjo 10.3 (Tree Star).
[0233] FACS sorting
[0234] For fluorescence activated cell sorting (FACS), CD8 +T cells were stained with anti-CD62L-APC (#21279626, LT-TD180, ImmunoTools) or anti-CD62L-PeCy7 (#304821, DREG-56, BioLegend) and anti-CD45RA-PB (#A74765, J.33, Beckman Coulter) antibodies. NV 、T CM and T EM CD8 + T cells were identified as CD62L + CD45RA + 、CD62L + CD45RA - and CD62L - CD45RA - The cells were isolated and sorted using a BD influx cell sorter (BD Bioscience). Cells were kept in R10 FBS at 37°C for at least 4 h before the experiment.
[0235] Western blotting
[0236] The cells were washed twice with PBS and lysed in ice-cold RIPA buffer (#89900, Thermo) supplemented with protease (#4693159001, Roche) and phosphatase inhibitors (#4906845001, Roche). The lysate was cleared by centrifugation and the protein concentration was assessed using the Pierce BCA protein assay kit (#23227, Thermo). Equal amounts of protein were loaded onto prefabricated micro PROTEAN TGX gels (#4568095, Biorad) and subjected to SDS-PAGE fractionation. After electrophoresis, total protein was assessed by a stain-free protocol from Biorad (5min ultraviolet (UV) activation followed by imaging with the GelDoc system). Then, the protein was transferred to a nitrocellulose membrane (#1704158, Biorad) and then blocked at room temperature for 1 h in a TBST solution of 5% BSA or milk. The membranes were incubated with the indicated primary antibodies overnight at 4°C, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies (1 h at room temperature). Enhanced chemiluminescence (ECL) was used to develop the western blots, the Geldoc system for imaging and ImageLab software for quantification (both from Biorad).
[0237] The following primary antibodies were used: anti-PHGDH (#66350, D8F30, Cell Signaling), anti-PHGDH (ab57030, abcam, used after IP of PHGDH), anti-PSAT1 (ab154055, abcam), anti-PSPH (ab211418, abcam), anti-SLC1A4 (#8442, Cell Signaling), anti-SLC1A5 (ASCT2) (#8057, D7C12, Cell Signaling), anti-SHMT1 (#12612, Cell Signaling), anti-SHMT2 (ab155230, abcam), anti-β-actin (#3700, 8H10D10, Cell Signaling). The following secondary antibodies were used: anti-rabbit IgG (#111-035-144, Jackson ImmunoResearch) and anti-mouse IgG (#115-035-003, Jackson ImmunoResearch).
[0238] PHGDH activity assay
[0239] The Jurkat T cells expressing the PHGDH variants were washed once in ice-cold PBS, snap frozen in liquid nitrogen and stored at -80°C until further use. On the day of the assay, the cell pellet was thawed, homogenized in lysis buffer (0.5MTris pH 8.5, 1mM EDTA, 0.02% Triton-X, 10mM NAD), and cell debris was removed by centrifugation (10 min at 4°C with 16000xg). The protein concentration of the clarified lysate was measured using Pierce BCA protein assay kit (#23227, Thermo). The protein amount was adjusted with assay buffer (50mM Tris pH 7.1, 10mM NAD) to make 50 μg of total protein in 150 μl of buffer. PHGDH activity was measured in two wells for each sample, once in the presence of the substrate 3-phospho-D-glyceric acid (3PG) (20 mM, P8877, Sigma) and once in the absence of the substrate - the final volume was always 200 μl. The NADH formation obtained by the catalytic activity of PHGDH was measured at 340 nm at room temperature using a Sinergy H1 microplate reader (Biotek). The PHGDH activity was then calculated by subtracting the absorbance value obtained in the absence of 3PG from the absorbance value obtained in the presence of 3PG.
[0240] Comparison of GAPDH and PHGDH by computer simulation
[0241] (1) Rossman fold: Based on the existing literature, the Rossman fold is highlighted. For GAPDH, this supersecondary structure is formed by residues 1-150 and 317-335 (White and Garcin, 2015). For PHGDH, consecutive residues 102 to 288 adopt the classic Rossman fold, which contains six-stranded parallel β sheets flanked by α helices on both sides. The crystal structure of human 3-phosphoglycerate dehydrogenase is available online: https: / / www.thesgc.org / sites / default / files / activeISee / PHGDHA_2g76_v5_351m / PHGDHA_2g76_v5_351m_Annotation.html Deposition Authors: Turnbull AP, Salah E, Savitsky P, Gileadi O, von Delft F, Edwards A, Arrowsmith C, Weigelt J, Sundstrom M, Oppermann (2006).
[0242] (2) Electrostatic potential: Adaptive Poisson-Boltzmann solver plug-in 3 Installed in Visual Molecular Dynamics (VMD) 4 The electrostatic potential is calculated above.
[0243] (3) Dimer interface: The GAPDH dimer interface is 5 In PHGDH, it is defined as 'antiparallel five-stranded β sheets from adjacent subunits'. For PHGDH, no consistent definition of the dimer interface in terms of residues or secondary structure was found in the literature. Importantly, the tetrameric form of PHGDH is arranged in different ways in different organisms, i.e., they form type I, type II or type III complexes. 6 Human PHGDH undergoes a complex type I structure in which three different dimer interfaces can be defined. Here, we define the interface as located as indicated by 6 The number of adjacent subunits in the defined I-R region is less than The residues within the tract are identified and the residues that form secondary structures containing these interacting residues are highlighted.
[0244] RNA immunoprecipitation sequencing (RIPseq) experiments
[0245] Immunoprecipitation: PHGDH-RNA complexes were isolated using Magna-RIP kit (#17-701, Millipore) according to the manufacturer's instructions. Briefly, approximately 10-15 Mio sorted T cells from 3 different human donors were NV Cells were activated for 36 h, washed once with PBS, resuspended in 210 μl RIP lysis buffer provided in the kit, and frozen at -80 ° C. After thawing, the lysed cells were centrifuged at 14000 rpm for 10 min at 4 ° C to clear the lysate. After taking out 10 μl-representative input samples, the resulting supernatant was evenly distributed in two test tubes. For IP, 4 μg of anti-PHGDH antibody (#66350, D8F30, Cell Signaling) or rabbit isotype matching IgG (ab172730, abcam) was used for 50 μL of magnetic protein A / G beads. Beads binding PHGDH and isotype control antibodies were added to one of the two test tubes per donor, and IP was performed overnight at 4 ° C. After several washes, aliquots of each sample were taken to test the efficiency of IP by Western blotting using mouse anti-PHGDH (ab57030, abcam) antibodies. From this time point on, the input RNA was treated equally again. After proteinase K digestion, RNA was isolated using TRIzol reagent (#15596026, Thermo) and Direct-zol RNA Microprep kit (#R2062, Zymo). RNA was eluted in 6 ul of RNase-free water.
[0246] RNA integrity and quantification: RNA molecules were quality checked on a bioanalyzer instrument (Agilent) using an RNA 6000Pico chip (#5067-1513, Agilent). The amount of RNA was quantified by fluorometry using the QuantiFluor RNA system (#E3310, Promega). Starting with 1 ng of total RNA, library preparation was performed using the SMART-Seq Standard Kit (#634444, Takara Bio). The library was sequenced for paired ends of 51 bases (in addition: 8 bases for index 1 and 8 bases for index 2) using a NovaSeq 6000 instrument (Illumina) and an SP Flow-Cell loaded at a final concentration of 400 pM in the flow lane and containing 1% PhiX. The primary data analysis was performed with Illumina RTA version 3.4.4. On average per sample: 38.3 ± 18.8 million reads that passed the filter were collected on the 1 SP Flow-Cell.
[0247] RNA sequencing data analysis: Read alignment was performed and count tables were obtained as described above. Data were normalized by applying the TMM method from the Bioconductor edgeR package (version 3.28.1) 7 Only genes with log2 CPM counts greater than 0 in at least 2 samples were retained for further analysis. The principal component analysis was based on the 25% most variable genes in the dataset. The quasi-likelihood (QL) method implemented in the edgeR package (version 3.28.1) was used. 8 , using replicate id as covariate, to identify differentially expressed genes.
[0248] Gene editing in primary human T cells before RNAseq
[0249] After sorting, T NV The cells were left to rest for 4 h. 2 Mio cells were harvested from each donor twice, washed once with PBS, and resuspended in 20 μl electroporation buffer from a P3 primary cell 96-well nuclear transfection kit (V4XP-3032, Lonza). 3 μM of RNP was added and electroporated with 4D-nucleofection (Amaxa-Lonza) program EH115. Immediately after electroporation, preheated R10FBS containing IL-2 (150 U / ml, Proleukin) was added to the cells and the cells were incubated for 24 h.
[0250] Activated PHGDH-KO T NV RNA sequencing of cells (RNAseq)
[0251] Total RNA was extracted from 2 Mio cells per condition from 5 human donors. RNA was extracted using the RNeasy mini kit (#74106, Qiagen) according to the manufacturer's protocol, which included on-column DNase (#79254, Qiagen) treatment.
[0252] Sample preparation and sequencing: RNA integrity was checked on a TapeStation instrument (Agilent) using RNA ScreenTape (#5067-5576, Agilent) and quantified by fluorometry using the QuantiFluor RNA system (#E3310, Promega). Starting from 200 ng of total RNA, library preparation was performed using the TruSeq Stranded mRNA Library Kit (#20020595, Illumina), TruSeq RNA UD Index (#20022371, Illumina) and TruSeq RNA CD Index Plate (#20019792, Illumina). 15 cycles of PCR were performed. The resulting libraries were sequenced for paired-end 101 bases (additional: 8 bases for index 1 and 8 bases for index 2) using a NovaSeq 6000 instrument (Illumina) and an S2 Flow-Cell loaded at a final concentration of 380 pM per flow lane and containing 1% PhiX. The primary data analysis was performed with Illumina RTA version 3.4.4. On average per sample: 69.1 ± 11.5 million reads passing the filter were collected on one S2 Flow-Cell.
[0253] RNA sequencing data analysis: using STAR (version 2.7.0c) 9 Reads were aligned to the human genome (UCSC version hg38 analysis set) with default parameters, except that up to 10 hits to the genome were allowed (outFilterMultimapNmax 10), only one position was reported for multi-mapped reads with equal scores (outSAMmultNmax 1), and reads with no evidence in the splice junction table were filtered (outFilterType "BySJout"). The output was sorted and indexed using samtools (v1.9). 10 Scaffold-specific coverage tracks for each sample were generated by tiling the genome in 20 bp windows and counting the 5' ends of reads per window using the function bamCount from the Bioconductor package bamsignals (v1.18.0). These window counts were calculated using the Bioconductor package rtracklayer (v1.46.0) 11 Export in bigWig format. Use Bioconductor package QuasR (v1.26.0) 12The qQCReport function of the Bioconductor package subread (v 2.0.1) was used to evaluate read and alignment quality, assuming an exon union model (using the gene model provided by ensembl v96). 13 featureCounts function to count the number of reads overlapping with the exons of each gene (5' end).
[0254] Recombinant Lentivirus Production
[0255] 24 hours before transfection, HEK-293 cells (5×10 6 cells / 5 ml medium) in 10 cm culture dishes. All plasmid DNAs were purified using the endotoxin-free plasmid Midiprep kit (Qiagen). HEK-293T cells were transfected with 9.15 μg pmol pSPAX2 (lentiviral packaging plasmid) and 2.77 μg pMD2G (VSV-G envelope expression plasmid) and 9.2 μg pLV-CAR:FMC63-BBZ-P2A-mCherry (CAR-mC) or pLV-CAR:FMC63-BBZ-P2A-PHGDH-P2A-mCherry (CAR-PHGDH-mC) using Lipofectamine 2000 (Invitrogen) and Optimem medium (Invitrogen, Life Technologies).
[0256] In some experiments, HEK-293T cells were transfected with 7.2 μg pCMVR8.74 (lentiviral packaging plasmid) and 2.8 μg pCMV-VSV-G (VSV-G envelope expression plasmid) and 6 μg pSFFV-PHGDH-IRES-GFP (encoding wild-type or catalytically inactive variants) using Lipofectamine 2000 (Invitrogen) and Optimem medium (Invitrogen, Life Technologies).
[0257] Viral supernatants were collected at 48 and 72 hours after transduction. Viral particles were concentrated using VIVASPIN 20 (Sartorius) and viral supernatants were stored at -80°C. Lentiviral particles of CAR constructs were generated as previously described.
[0258] Protocol for lentiviral transduction
[0259] Blood samples were obtained from healthy donors after written informed consent. Peripheral blood mononuclear cells (PBMCs) were isolated by standard density gradient centrifugation protocol (Lymphoprep; Fresenius Kabi). CD3 + T cells are positively selected. + T cells were seeded into 24-well cell culture plates and stimulated with beads coated with anti-CD3 and anti-CD28 monoclonal antibodies (Invitrogen, Life Technologies) at a 1:1 ratio or with ImmunoCult Humam CD3 / CD28 T cell activator (Stemcell) in R10AB containing IL-2 (150 U / ml). At 18-22 hours after activation, T cells were transduced with lentiviral particles in cell culture plates coated with polybrene (Sigma, 6 μg / ml), followed by a spinoculation step at 1000×g for 60 min at 30°C.
[0260] The medium was replaced with fresh IL-2 (150 U / ml) every 2 days. Five days after transduction, the cells were analyzed for transduction efficiency by analyzing mCherry or GFP expression using flow cytometry. Samples were acquired using a CytoFLEX flow cytometer (Beckman Coulter). Data were analyzed using ELISA_V10.5 (Tree Star, USA).
[0261] To achieve pure CAR T cell populations, cells were sorted based on mCherry expression (CD19-CAR) or both mCherry and GFP (CD19-CAR_PHGDH). In experiments where cells were transduced with pSFFV-PHGDH-IRES-GFP and pLV-CAR:FMC63-BBZ-P2A-mCherry constructs, double positive cells were sorted using a BD influx cell sorter (BD Bioscience).
[0262] Proliferation of transduced T cells
[0263] The sorted T cells expressing CD19 CAR or CD19 CAR_PHGDH (CD) were divided into two groups in equal numbers (2×10 5 Cells were seeded in 96-well plates in R10FBS containing IL-2 (150 U / ml). Cell numbers were determined by counting cells at designated time points.
[0264] animal
[0265] C57BL / 6 (CD45.1 and CD45.2 and Thy1.1 and Thy1.2) were purchased from Charles River Laboratories. OT-I mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were housed under specific pathogen-free conditions at McGill University (Canada), the Van Andel Institute (USA), and the University of Basel according to approved protocols. NOD.Cg-Prkdc <scid>Il2rg <tm1wjl>SzJ (NSG) mice were bred and housed under specific pathogen-free (SPF) conditions at the University of Basel. Experiments were performed between 6 and 20 weeks of age.
[0266] Mouse T cell isolation
[0267] After euthanasia in a CO2 chamber, spleens were harvested and pushed through a 70 μm cell strainer (#431751, Corning). Red blood cells (RBCs) were then removed from the single-cell suspension using RBC-lysis buffer (154 mM NH4CL, 10 mM KHCO3, and 0.1 mM EDTA) and lysed with CD8a-microbeads (#130-117-004, Miltenyi Biotec) when indicated. + T cells were isolated by MACS.
[0268] FACS sorting of T cell subsets
[0269] Mouse MACS-enriched CD8 was stained with anti-CD8a-BV510, anti-CD44-AF647, and CD62L-BV421 antibodies on ice. + T cells were stained for 30 min. After washing twice with FACS buffer, cells were sorted into T cells on a BD FACS-Aria. NV Cells (CD8 + CD62L + CD44 - ) and T EM Cells (CD8 + CD62L - CD44 + ).
[0270] Adoptive transfer experiments
[0271] 293T cells were transfected with plasmid constructs containing WT PHGDH (MigR1-PHGDH-IRES-EGFP; OE-PHGDH or OE-WT) or CD PHGDH (MigR1-PHGDH-IRES-EGFP; OE-CD) and a control vector (MigR1-IRES-EGFP; EV) together with pCMV-VSVG (Addgene). The supernatant containing retrovirus was cleaned by 0.45 μm filtration and mixed with polybrene. Naive CD8 + Thy1.1 + OT-I T cells for one day. Activated T cells were spin-transduced with EV or OE-PHGDH / OE-WT or OE-CD retroviral particles. After 24 h of incubation, the cell culture medium containing 50 U / ml of IL-2 was replaced and the cells were expanded for an additional 24 h before GFP-FACS sorting. The cells were allowed to rest for 24 h and then adoptively transferred into C57BL / 6 mice (5000 cells / mouse). One day after transfer, mice were infected intravenously with attenuated LmOVA. Blood was sampled at designated time points after infection for analysis of all CD8 + Adoptively transferred Thy1.1 in T cells + GFP + The frequency of cells.
[0272] In vivo infection model
[0273] For memory rechallenge experiments, in EV and OE-PHGDH-CD CD8 + Thy1.1 + After adoptive transfer of T cells, mice were immunized with a sublethal dose of recombinant attenuated Listeria monocytogenes (Lm) expressing OVA (attLmOVA, 2×106 CFU). 35 days after the initial infection, animals were reinfected with a lethal dose of recombinant virulent LmOVA (virLmOVA, 1×106 CFU), and blood was sampled at designated time points. Th1.1 was determined by flow cytometry using an LSR Fortessa (BD Biosciences) flow cytometer + GFP + CD8 + Frequency of Thy1.1+ T cells.
[0274] Anti-CD19 CAR T cell in vivo experiments
[0275] CAR-mC and CAR-PHGDH-mC T cells were generated as described above and expanded for 12 days, with medium replacement every 2 days with fresh IL-2 (150 U / ml). The transduction efficiency of CAR T cells was analyzed by flow cytometry analysis of mCherry expression.
[0276] Ten days before adoptive transfer, female NSG mice (6-9 weeks old) were injected subcutaneously with 5×10 5 Ramos cells (ATCC). On the day of adoptive transfer, CAR cells were counted and the cell number was adjusted so that 1×10 6 CAR T cells.
[0277] In order to evaluate the in vivo persistence of CAR T cells, spleens were harvested and single cell suspensions were generated. The spleens were manually homogenized in PBS and passed through a 70-μm cell strainer (BD Biosciences). Red blood cells were lysed using ACK (ammonium potassium chloride) lysis buffer (BD Biosciences). In order to determine the number of CAR T cells, single cell suspensions were analyzed by flow cytometry.
[0278] Gene editing of primary human T cells prior to deep proteomic analysis
[0279] After sorting, T NV The cells were left to rest for 4 h. 2 Mio cells were harvested from each donor twice, washed once with PBS, and resuspended in 20 μl electroporation buffer from a P3 primary cell 96-well nuclear transfection kit (V4XP-3032, Lonza). 3 μM of RNP was added and electroporated with 4D-nucleofection (Amaxa-Lonza) program EH115. Immediately after electroporation, preheated R10FBS containing IL-2 (150 U / ml, Proleukin) was added to the cells and the cells were incubated for 24 h.
[0280] Deep proteomic analysis based on 16-plex TMT
[0281] Proteins were extracted from approximately 4 million T cells using 50 μL of lysis buffer and sonication (30 seconds on, 30 seconds off, 10 cycles = 10 min). The samples were then heated at 95°C for 10 minutes and cooled to room temperature. Alkylation of the proteins was performed by adding 1 μL of 0.75 M chloroacetamide solution and incubating at 37°C at 500 rpm for 30 minutes.
[0282] Protein digestion was performed by adding trypsin at a final enzyme to protein ratio of 1:50 and digesting overnight at 37°C. 50 μL of 5% TFA was then added to the sample, vortexed and transferred to a PreOmics 96 plate cartridge. Peptides were automatically desalted using a Tecan A200 and then dried.
[0283] 200 μL of wash buffer was loaded into the solid phase in the cartridge and washed by spinning at 2,000 x g for 4 minutes. This step was repeated twice. The cartridge was then placed on a new plate and the peptides were eluted with 2 x 100 μL of elution buffer (2,000 x g, 2 minutes) and dried in a speed vac.
[0284] For TMT labeling of peptides, 10 μg of total protein / peptide per sample was used. The samples were dissolved in 10 μL labeling buffer, and 0.5 μL of ProtMix 1 was added to sample 1, 0.5 μL of ProtMix 2 was added to sample 2, and so on. 2.5 μL of TMTpro reagent was then added, and the samples were left in a thermomixer at 25°C at 500 rpm for 1 hour. The reaction was terminated by adding 0.75 μL of stop solution. All samples were then combined into a single 2 ml Eppendorf tube, and 110 μL of high pH buffer was added. 110 μL of 2M HCl was added to 2 ml of Eppendorf 16-plex sample to neutralize the high pH buffer, and 27.5 μL of 5% TFA was added. For solid phase extraction of TMT-labeled peptides, a C18 column was conditioned with 400 μL of acetonitrile and equilibrated with buffer. The samples were then loaded onto the column and washed with buffer. The peptides were eluted, dried and resuspended in 16 μL of chromatography buffer (0.5 μg / μL). 1.6 μL of 1:10 iRT-peptide mixture was added and submitted for LC-MS / MS analysis.
[0285] Actinomycin D chase experiment-RNA stability assay
[0286] Prior to PHGDH CRISPR KO, sorted CD8 + T NV The cells were incubated at 37°C for 4 h. 24 h after CRISPR, the cells were stimulated with beads coated with anti-CD3 and anti-CD28 monoclonal antibodies for 3 days, after which the beads were removed. The cells were treated with actinomycin D (5 μg / ml) and harvested at 0 h, 1 h, 2 h, and 3 h after treatment. Total RNA was extracted from the cells
[0287] RNA was isolated from T cells using the RNeasy micro kit (#74106, Qiagen) according to the manufacturer's protocol and then purified using the RNeasy RNA purification micro kit (QIAGEN, Germany). RNA concentration was determined using NanoDrop 2000C (Thermo Fisher Scientific). Based on equal amounts of purified RNA, reverse transcriptase kit GoScript TM cDNA was synthesized by reverse transcriptase (Promega). Quantitative PCR of IRF1 mRNA was performed in triplicate using the following primer pairs: fw: GTACCGGATGCTTCCACCTC (SEQ ID NO: 5), rev: GTCCGGCACAACTTCCACT (SEQ ID NO: 6). PCR reactions were performed using Go Tag G2 Green Master Mix (Promega) according to the manufacturer's protocol. Half-life was determined relative to time point 0 of actinomycin D treatment.
[0288] Microscale thermophoresis-RNA binding assay
[0289] Recombinant human PHGDH was purchased from Abcam (ab198455). Single-stranded RNA fragments encoding various parts of the 3'UTR of IRF1 were purchased from IDT using their RNA oligomer-specific tool:
[0290] Fragment 3: 5'-AGGAAUUGAACUUUUAAUUGCAUUUAATAAACUGUAUGUAAAUAGUCA-3' (SEQ IDNO: 7)
[0291] Fragment fg4: 5′-ACAUGUGCCAGCUAAGCACUUGAAAUGUGGCCAGUGCAAUA-3′
[0292] (SEQ ID NO:8)
[0293] Mutation fragment 3: 5'-AGGAAUUGAACCCUUAAUUGCAUUUAAUAAACUGUAUGUAAAUAGUCA-3' (SEQ ID NO: 9)
[0294] The fragments were resuspended in IDTE buffer (30 mM HEPES, pH 7.5, 100 mM potassium acetate).
[0295] Use a blue filter and a red filter Microscale thermophoresis experiments were performed using Monolith NT.115 (NanoTemper Tenchologies, Germany). The His-tagged PHGDH protein was labeled using the Monolith His-Tag Labeling Kit RED-Tris-NTA Second Generation (SKU: MO-L018) according to the manufacturer's protocol (Step B, Step C). Briefly, 90 μl of PHGDH protein (200 nM) was mixed with 90 μl of dye (100 nM) and incubated at room temperature for 30 min. The samples were centrifuged at 15.000 x g for 10 min at 4 ° C and transferred to a new tube. RNA was adjusted to a concentration of 1700 nM and a 1:2 serial dilution was performed in 16 steps in binding buffer (10 mM Tris HCl, 50 mM KCl, 0.5 mM EDTA, 0.1 mg / ml BSA, 10% (v / v) RNase / DNase-free glycerol). Fluorescently labeled proteins were added to each test tube at a final concentration of 50 nM. IRF1 3'UTR RNA (maximum concentration 850 nM) and PHGDH protein (50 nM) were loaded into 16 capillaries. Samples were measured using the following settings: 20% LED / excitation and medium MST power. At a final dye concentration of 25 nM, the expected fluorescence intensity at 20% LED / excitation on Monolith NT.115 is approximately 300 counts.
[0296] Quantification and statistical analysis
[0297] All graphs, curve fitting and statistical analyses were performed using GraphPad Prism. P values less than 0.05 were considered statistically significant.
[0298] References
[0299] 1)Bantug et al.,2018(doi:10.1016 / j.immuni.2018.02.012)
[0300] 2)Fischer et al., 2018(doi:10.1002 / eji.201747443)
[0301] 3)Baker et al.,2001(doi.org / 10.1073 / pnas.181342398)
[0302] 4)Humphrey et al.,1996(doi:10.1016 / 0263-7855(96)00018-5)
[0303] 5)White and Garcin,2015(doi:10.1002 / wrna.1315)
[0304] 6)Grant,2018(doi:10.3389 / fmolb.2018.00110)
[0305] 7)Robinson et al., 2010(doi:10.1093 / bioinformatics / btp616)
[0306] 8)Lund et al., 2012(doi:10.1515 / 1544-6115.1826)
[0307] 9)Dobin et al., 2013(doi.org / 10.1093 / bioinformatics / bts635)
[0308] 10)Li et al., 2009(doi:10.1093 / bioinformatics / btp352)
[0309] 11) Lawrence et al., 2009(doi:10.1093 / bioinformatics / btp328)
[0310] 12) Gaidatzis et al., 2015(doi.org / 10.1093 / bioinformatics / btu781)
[0311] 13)Liao et al., 2019(doi:10.1093 / nar / gkz114)
[0312] All publications, patents and patent applications, including any figures and appendices therein, are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent or patent application, figure or appendix was specifically and individually indicated as being incorporated by reference in its entirety for all purposes.
[0313] Reference in this specification to any previous publication (or information derived therefrom) or any known matter is not and should not be taken as an acknowledgement or approval or any form of implication that the previous publication (or information derived therefrom) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. < / scid>
Claims
1. A cell genetically engineered to enhance the expression of phosphoglycerate dehydrogenase (PHGDH).
2. The cell according to claim 2, wherein the cell is used in cell therapy.
3. The cell according to claim 1 or 2, wherein the cell is an immune cell.
4. The cell of claim 3, wherein the cell is a T cell, optionally comprising a chimeric antigen receptor (CAR).
5. The cell according to any one of claims 1 to 4, comprising an exogenous polynucleotide sequence encoding PHGDH.
6. The cell according to claim 5, wherein the polynucleotide sequence comprises SEQ ID NO: 4 or a sequence having 95% identity with SEQ ID NO: 4, and wherein the sequence encodes a polypeptide having RNA binding activity, or a variant or functional fragment thereof.
7. The cell according to claim 5 or 6, comprising a polynucleotide sequence encoding CAR.
8. An expression cassette comprising a polynucleotide sequence encoding phosphoglycerate dehydrogenase (PHGDH).
9. The expression cassette of claim 8, for genetic modification of cell therapy.
10. The expression cassette according to claim 8 or 9, wherein the polynucleotide sequence comprises SEQ ID NO: 4 or a sequence having 95% identity with SEQ ID NO: 4, and wherein the sequence encodes a polypeptide having RNA binding activity, or a variant or functional fragment thereof.
11. The expression cassette according to any one of claims 8 to 10, wherein the polynucleotide sequence comprises in the following 5' to 3' order: a) a promoter sequence, and b) Sequence encoding PHGDH.
12. The expression cassette of any one of claims 8 to 11, further comprising a polynucleotide sequence encoding a chimeric antigen receptor (CAR).
13. A vector comprising a polynucleotide sequence encoding phosphoglycerate dehydrogenase (PHGDH), optionally wherein the polynucleotide sequence comprises SEQ ID NO:4 or a sequence with 95% identity to SEQ ID NO:4, and wherein the sequence encodes a polypeptide having RNA binding activity, or a variant or functional fragment thereof.
14. A vector comprising the expression cassette according to any one of claims 8 to 12.
15. The vector according to claim 13 or 14, wherein the vector is a lentiviral vector (LV), preferably a LV expression vector.
16. A cell comprising the expression cassette of any one of claims 8 to 12 or the vector of any one of claims 13 to 15.
17. A composition comprising a cell according to any one of claims 1 to 7 or claim 16, an expression cassette according to any one of claims 8 to 12, or a vector according to any one of claims 13 to 15.
18. A method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a cell according to any one of claims 1 to 7 or claim 16, an expression cassette according to any one of claims 8 to 12, a vector according to any one of claims 13 to 15, or a composition according to claim 17.
19. The method of claim 18 or the cell, expression cassette, vector or composition for use according to claim 19, wherein the disease or disorder is cancer or infection.
20. The method of claim 18 or 19, wherein the method comprises a cell therapy method and wherein the cells according to any one of claims 1 to 7 or claim 16 or the composition according to claim 17 comprising the cells according to any one of claims 1 to 7 or claim 16 are administered to the subject.
21. The cell of any one of claims 1 to 7 or claim 16, the expression cassette of any one of claims 8 to 12, the vector of any one of claims 13 to 15 or the composition of claim 17 for use in a method of treating a disease or disorder in a subject.
22. A method for producing cells genetically engineered to enhance expression of phosphoglycerate dehydrogenase (PHGDH), the method comprising contacting one or more cells with the vector according to any one of claims 13 to 15.
